AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. NXTC
  4. [10-Q] NextCure, Inc. Quarterly Earnings Report

[10-Q] NextCure, Inc. Quarterly Earnings Report

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
10-Q
Rhea-AI Filing Summary

NextCure鈥檚 Q2-25 10-Q shows a sharp deterioration in liquidity and higher losses driven by a new licensing deal. Cash & equivalents fell to $4.9 m (-82%) and marketable securities to $30.4 m, leaving $35.3 m available versus $68.6 m at YE-24. Management expects this to fund operations only into mid-2026 and discloses substantial doubt about going concern.

Operating expenses jumped 65% YoY to $27.3 m. R&D doubled to $24.1 m, primarily due to a $17 m up-front/I-PR&D charge for the June 2025 SIM0505 ADC license from Zaiming. G&A fell 22% to $3.2 m after a 2024 restructuring. Q2 net loss widened to $26.8 m (-$11.29/sh) from $15.4 m (-$6.61/sh) a year earlier; 1H-loss is $37.8 m.

The company raised only $2 m via a private placement (338.6 k shares at $5.904) classified as mezzanine equity until SEC registration (completed 29-Jul-25). A 1-for-12 reverse split effective 14-Jul-25 restored Nasdaq bid-price compliance, leaving 2.68 m shares outstanding on 4-Aug-25.

Pipeline: Phase 1 B7-H4 ADC LNCB74 cleared cohort 3 and expects back-fill cohorts 2H-25 with PoC read-out 1H-26. SIM0505 IND transferred from partner; first US patient expected 3Q-25. Cost-share ADC collaboration with LigaChem produced a $1 m receivable.

Key balance-sheet items (Jun-25 vs Dec-24):

  • Total assets: $47.7 m vs $80.9 m
  • Accum. deficit: $417.9 m (was $380.1 m)
  • Equity: $29.6 m vs $65.5 m
Absent partnerships or financing, further dilution or program delays appear likely.

Il 10-Q del secondo trimestre 2025 di NextCure evidenzia un netto peggioramento della liquidit脿 e perdite maggiori causate da un nuovo accordo di licenza. La liquidit脿 e gli equivalenti sono scesi a 4,9 milioni di dollari (-82%) e i titoli negoziabili a 30,4 milioni di dollari, lasciando 35,3 milioni di dollari disponibili rispetto ai 68,6 milioni di fine 2024. La direzione prevede che questi fondi copriranno le operazioni solo fino a met脿 2026 e dichiara un grave dubbio sulla continuit脿 aziendale.

Le spese operative sono aumentate del 65% su base annua, raggiungendo 27,3 milioni di dollari. La R&S 猫 raddoppiata a 24,1 milioni, principalmente a causa di un costo anticipato di 17 milioni di dollari per ricerca e sviluppo I-PR&D legato alla licenza SIM0505 ADC da Zaiming di giugno 2025. Le spese generali e amministrative sono diminuite del 22% a 3,2 milioni dopo una ristrutturazione nel 2024. La perdita netta del secondo trimestre si 猫 ampliata a 26,8 milioni (-11,29 dollari per azione) rispetto a 15,4 milioni (-6,61 dollari per azione) dell鈥檃nno precedente; la perdita del primo semestre 猫 di 37,8 milioni.

L鈥檃zienda ha raccolto solo 2 milioni tramite un collocamento privato (338,6 mila azioni a 5,904 dollari), classificato come capitale mezzanino fino alla registrazione presso la SEC (completata il 29 luglio 2025). Un split inverso 1-per-12 efficace dal 14 luglio 2025 ha ripristinato la conformit脿 al prezzo minimo di offerta Nasdaq, lasciando 2,68 milioni di azioni in circolazione al 4 agosto 2025.

Pipeline: La fase 1 dell鈥橝DC B7-H4 LNCB74 ha superato il terzo gruppo di pazienti e prevede di integrare nuovi gruppi nella seconda met脿 del 2025 con risultati di prova di concetto nella prima met脿 del 2026. L鈥橧ND di SIM0505 猫 stato trasferito dal partner; il primo paziente negli Stati Uniti 猫 atteso nel terzo trimestre 2025. La collaborazione per la condivisione dei costi con LigaChem ha generato un credito di 1 milione di dollari.

Elementi chiave del bilancio (giugno 2025 vs dicembre 2024):

  • Attivit脿 totali: 47,7 milioni di dollari vs 80,9 milioni
  • Perdita accumulata: 417,9 milioni (era 380,1 milioni)
  • Patrimonio netto: 29,6 milioni vs 65,5 milioni
In assenza di partnership o nuovi finanziamenti, appaiono probabili ulteriori diluizioni o ritardi nei programmi.

El informe 10-Q del segundo trimestre de 2025 de NextCure muestra un marcado deterioro en la liquidez y mayores p茅rdidas impulsadas por un nuevo acuerdo de licencia. El efectivo y equivalentes cayeron a 4,9 millones de d贸lares (-82%) y los valores negociables a 30,4 millones, dejando 35,3 millones disponibles frente a 68,6 millones al cierre de 2024. La direcci贸n espera que estos fondos financien las operaciones solo hasta mediados de 2026 y declara dudas sustanciales sobre la continuidad operativa.

Los gastos operativos aumentaron un 65% interanual a 27,3 millones. I+D se duplic贸 a 24,1 millones, principalmente debido a un cargo inicial de 17 millones de d贸lares por investigaci贸n y desarrollo I-PR&D relacionado con la licencia SIM0505 ADC de junio de 2025 de Zaiming. Los gastos generales y administrativos cayeron un 22% a 3,2 millones tras una reestructuraci贸n en 2024. La p茅rdida neta del segundo trimestre se ampli贸 a 26,8 millones (-11,29 d贸lares por acci贸n) desde 15,4 millones (-6,61 d贸lares por acci贸n) un a帽o antes; la p茅rdida del primer semestre es de 37,8 millones.

La compa帽铆a recaud贸 solo 2 millones mediante una colocaci贸n privada (338,6 mil acciones a 5,904 d贸lares), clasificada como capital mezzanine hasta la inscripci贸n en la SEC (completada el 29 de julio de 2025). Un split inverso de 1 por 12 efectivo el 14 de julio de 2025 restaur贸 el cumplimiento del precio m铆nimo en Nasdaq, dejando 2,68 millones de acciones en circulaci贸n al 4 de agosto de 2025.

Pipeline: La fase 1 del ADC B7-H4 LNCB74 super贸 la cohorte 3 y espera completar cohortes adicionales en la segunda mitad de 2025 con resultados de prueba de concepto en la primera mitad de 2026. El IND de SIM0505 fue transferido del socio; se espera el primer paciente en EE.UU. en el tercer trimestre de 2025. La colaboraci贸n de ADC con LigaChem para compartir costos gener贸 una cuenta por cobrar de 1 mill贸n.

Elementos clave del balance (junio 2025 vs diciembre 2024):

  • Activos totales: 47,7 millones vs 80,9 millones
  • D茅ficit acumulado: 417,9 millones (antes 380,1 millones)
  • Patrimonio: 29,6 millones vs 65,5 millones
Sin asociaciones o financiamiento, parecen probables nuevas diluciones o retrasos en los programas.

NextCure鞚� 2025雲� 2攵勱赴 10-Q 氤搓碃靹滊姅 鞁犼窚 霛检澊靹犾姢 瓿勳暯鞙茧 鞚疙暣 鞙犽彊靹� 旮夑皭瓿� 靻愳嫟 歃濌皜毳� 氤挫棳欷嶋媹雼�. 順勱笀 氚� 順勱笀靹� 鞛愳偘鞚� 490毵� 雼煬(-82%)搿� 臧愳唽頄堦碃, 鞁滌灔靹� 歃濌秾鞚� 3,040毵� 雼煬搿� 欷勳柎 2024雲� 毵� 6,860毵� 雼煬鞐愳劀 3,530毵� 雼煬毵� 靷毄 臧�電ロ晿瓴� 霅橃棃鞀惦媹雼�. 瓴届榿歆勳潃 鞚� 鞛愱笀鞚� 2026雲� 欷戨皹旯岇 鞖挫榿 鞛愱笀鞙茧 於╇秳頃� 瓴冹溂搿� 鞓堨儊頃橂┌, 旮办梾 臁挫啀鞐� 雽�頃� 欷戨寑頃� 鞚橂鞚� 響滊獏頄堨姷雼堧嫟.

鞓侅梾牍勳毄鞚� 鞝勲厔 雽�牍� 65% 歃濌皜頃� 2,730毵� 雼煬毳� 旮半頄堨姷雼堧嫟. 鞐瓣惮臧滊皽牍勲姅 欤茧 2025雲� 6鞗� Zaiming鞙茧攵�韯� 氚涭潃 SIM0505 ADC 霛检澊靹犾姢 甏�霠� 1,700毵� 雼煬鞚� 靹犼笁 I-PR&D 牍勳毄鞙茧 鞚疙暣 2,410毵� 雼煬搿� 霊� 氚瓣皜 霅橃棃鞀惦媹雼�. 鞚茧皹甏�毽箘電� 2024雲� 甑“臁办爼 鞚错泟 22% 臧愳唽頃� 320毵� 雼煬毳� 旮半頄堨姷雼堧嫟. 2攵勱赴 靾滌啇鞁れ潃 2,680毵� 雼煬(-欤茧嫻 11.29雼煬)搿� 鞝勲厔 霃欔赴 1,540毵� 雼煬(-欤茧嫻 6.61雼煬)鞐愳劀 頇曤寑霅橃棃鞙茧┌, 靸侂皹旮� 靻愳嫟鞚� 3,780毵� 雼煬鞛呺媹雼�.

須岇偓電� 靷 氚滍枆鞚� 韱淀暣 200毵� 雼煬(欤茧嫻 5.904雼煬鞐� 33毵� 8,600欤�)毵� 臁半嫭頄堨溂氅�, SEC 霌彪 鞕勲(2025雲� 7鞗� 29鞚�) 鞝勱箤歆� 氅旍瀽雼� 鞛愲掣鞙茧 攵勲霅橃棃鞀惦媹雼�. 2025雲� 7鞗� 14鞚� 氚滍毃霅� 1雽� 12 鞐硲頃�鞙茧 雮橃姢雼� 鞛呾鞍臧� 旮办鞚� 須岆车頄堨溂氅�, 2025雲� 8鞗� 4鞚� 旮办 氚滍枆 欤检嫕 靾橂姅 268毵� 欤检瀰雼堧嫟.

韺岇澊頂勲澕鞚�: 1靸� B7-H4 ADC LNCB74電� 3氩堨Ц 旖旐樃韸鸽ゼ 韱店臣頄堨溂氅�, 2025雲� 頃橂皹旮办棎 於旉皜 旖旐樃韸鸽ゼ 毂勳毎瓿� 2026雲� 靸侂皹旮办棎 臧滊厫 歃濍獏 瓴瓣臣毳� 旮半寑頃橁碃 鞛堨姷雼堧嫟. SIM0505 IND電� 韺岉姼雱堧攵�韯� 鞚挫爠霅橃棃鞙茧┌, 氙戈淡 觳� 頇橃瀽電� 2025雲� 3攵勱赴鞐� 鞓堨儊霅╇媹雼�. LigaChem瓿检潣 牍勳毄 攵勲嫶 ADC 順戨牓鞙茧 100毵� 雼煬鞚� 氙胳垬旮堨澊 氚滌儩頄堨姷雼堧嫟.

欤检殧 鞛 頃(2025雲� 6鞗� vs 2024雲� 12鞗�):

  • 齑� 鞛愳偘: 4,770毵� 雼煬 vs 8,090毵� 雼煬
  • 雸勳爜 鞝侅瀽: 4鞏� 1,790毵� 雼煬 (鞚挫爠 3鞏� 8,010毵� 雼煬)
  • 鞛愲掣: 2,960毵� 雼煬 vs 6,550毵� 雼煬
韺岉姼雱堨嫮鞚措倶 於旉皜 鞛愱笀 臁半嫭 鞐嗢澊電� 於旉皜 頋劃鞚措倶 頂勲攴鸽灗 歆�鞐办澊 鞓堨儊霅╇媹雼�.

Le rapport 10-Q du deuxi猫me trimestre 2025 de NextCure r茅v猫le une forte d茅t茅rioration de la liquidit茅 et des pertes accrues dues 脿 un nouvel accord de licence. La tr茅sorerie et les 茅quivalents ont chut茅 脿 4,9 millions de dollars (-82 %) et les titres n茅gociables 脿 30,4 millions, laissant 35,3 millions disponibles contre 68,6 millions 脿 la fin 2024. La direction pr茅voit que ces fonds ne financeront les op茅rations que jusqu'脿 la mi-2026 et exprime un doute important sur la continuit茅 d鈥檈xploitation.

Les d茅penses d鈥檈xploitation ont bondi de 65 % en glissement annuel 脿 27,3 millions. La R&D a doubl茅 脿 24,1 millions, principalement en raison d鈥檜ne charge initiale de 17 millions de dollars pour I-PR&D li茅e 脿 la licence ADC SIM0505 de juin 2025 accord茅e par Zaiming. Les frais g茅n茅raux et administratifs ont diminu茅 de 22 % 脿 3,2 millions apr猫s une restructuration en 2024. La perte nette du T2 s鈥檈st creus茅e 脿 26,8 millions (-11,29 $ par action) contre 15,4 millions (-6,61 $ par action) un an plus t么t ; la perte du premier semestre est de 37,8 millions.

La soci茅t茅 n鈥檃 lev茅 que 2 millions via un placement priv茅 (338,6 k actions 脿 5,904 $), class茅 en quasi-fonds propres jusqu鈥櫭� l鈥檈nregistrement aupr猫s de la SEC (achev茅 le 29 juillet 2025). Un split invers茅 1 pour 12 effectif au 14 juillet 2025 a r茅tabli la conformit茅 au prix plancher Nasdaq, laissant 2,68 millions d鈥檃ctions en circulation au 4 ao没t 2025.

Pipeline : La phase 1 de l鈥橝DC B7-H4 LNCB74 a franchi la cohorte 3 et pr茅voit de compl茅ter les cohortes au second semestre 2025 avec un r茅sultat de preuve de concept au premier semestre 2026. L鈥橧ND SIM0505 a 茅t茅 transf茅r茅e du partenaire ; le premier patient am茅ricain est attendu au T3 2025. La collaboration ADC en partage de co没ts avec LigaChem a g茅n茅r茅 une cr茅ance de 1 million.

Principaux 茅l茅ments du bilan (juin 2025 vs d茅cembre 2024) :

  • Actifs totaux : 47,7 M$ contre 80,9 M$
  • D茅ficit accumul茅 : 417,9 M$ (contre 380,1 M$)
  • Capitaux propres : 29,6 M$ contre 65,5 M$
En l'absence de partenariats ou de financements, de nouvelles dilutions ou des retards dans les programmes semblent probables.

Der 10-Q-Bericht von NextCure f眉r das zweite Quartal 2025 zeigt eine deutliche Verschlechterung der Liquidit盲t und h枚here Verluste, verursacht durch einen neuen Lizenzvertrag. Zahlungsmittel und 脛quivalente fielen auf 4,9 Mio. USD (-82%) und marktf盲hige Wertpapiere auf 30,4 Mio. USD, womit 35,3 Mio. USD verf眉gbar sind gegen眉ber 68,6 Mio. USD zum Jahresende 2024. Das Management erwartet, dass diese Mittel nur bis Mitte 2026 f眉r den Betrieb ausreichen und 盲u脽ert .

Die Betriebsausgaben stiegen im Jahresvergleich um 65 % auf 27,3 Mio. USD. Die F&E-Kosten verdoppelten sich auf 24,1 Mio. USD, haupts盲chlich aufgrund einer 17 Mio. USD Vorab-/I-PR&D-Aufwendung f眉r die im Juni 2025 von Zaiming erworbene SIM0505 ADC-Lizenz. Die allgemeinen Verwaltungskosten sanken nach einer Umstrukturierung 2024 um 22 % auf 3,2 Mio. USD. Der Nettoverlust im 2. Quartal weitete sich auf 26,8 Mio. USD (-11,29 USD je Aktie) aus, verglichen mit 15,4 Mio. USD (-6,61 USD je Aktie) im Vorjahr; der Verlust im ersten Halbjahr betr盲gt 37,8 Mio. USD.

Das Unternehmen erzielte nur 2 Mio. USD durch eine Privatplatzierung (338.600 Aktien zu 5,904 USD), die bis zur SEC-Registrierung (abgeschlossen am 29. Juli 2025) als Mezzanine-Kapital klassifiziert wurde. Ein 1-zu-12 Reverse Split, wirksam ab dem 14. Juli 2025, stellte die Einhaltung der Nasdaq-Notierungsanforderungen wieder her und lie脽 am 4. August 2025 2,68 Mio. ausstehende Aktien verbleiben.

Pipeline: Die Phase-1-Studie des B7-H4 ADC LNCB74 hat Kohorte 3 abgeschlossen und plant, im zweiten Halbjahr 2025 weitere Kohorten zu erg盲nzen, mit einem Proof-of-Concept-Ergebnis in der ersten H盲lfte 2026. Die IND f眉r SIM0505 wurde vom Partner 眉bertragen; der erste US-Patient wird im 3. Quartal 2025 erwartet. Die ADC-Kostenbeteiligungs-Kooperation mit LigaChem brachte eine Forderung 眉ber 1 Mio. USD ein.

Wichtige Bilanzposten (Juni 2025 vs. Dezember 2024):

  • Gesamtverm枚gen: 47,7 Mio. USD vs. 80,9 Mio. USD
  • Kumuliertes Defizit: 417,9 Mio. USD (vorher 380,1 Mio. USD)
  • Eigenkapital: 29,6 Mio. USD vs. 65,5 Mio. USD
Ohne Partnerschaften oder Finanzierung erscheinen weitere Verw盲sserungen oder Programmverz枚gerungen wahrscheinlich.

Positive
  • Pipeline expansion: acquisition of SIM0505 adds a second clinical-stage ADC program with global rights ex-China.
  • Clinical progress: LNCB74 cleared third dose cohort; back-fill cohorts slated for 2H-25, keeping timeline intact.
  • Nasdaq compliance restored via 1-for-12 reverse stock split, reducing delisting risk.
Negative
  • Substantial doubt about going concern; cash only funds operations into mid-2026 at current burn.
  • Cash & securities declined 49% in six months to $35.3 m amid $35.7 m operating outflow.
  • Quarterly net loss widened 74% YoY to $26.8 m driven by $17 m IPR&D charge.
  • Potential dilution: limited share count post-split and need for additional capital could significantly dilute holders.
  • Mezzanine equity issuance highlights reliance on small private placements.

Insights

TL;DR: Heavy R&D charge drains cash; license adds pipeline depth but heightens financing risk.

The $17 m SIM0505 upfront creates strategic value鈥攄iversifies into CDH6 ADCs with a late-Phase 1 asset鈥攜et the accounting hit inflates quarterly loss and accelerates cash burn to ~$18 m/quarter. Cash runway to mid-2026 assumes no acceleration in trial pace; two dose-escalation studies plus back-fill cohorts could push burn higher. Management鈥檚 acknowledgment of going-concern doubt underscores near-term capital needs. Reverse split repairs Nasdaq listing but does not solve dilution risk; with only 2.7 m post-split shares, any sizeable raise could be highly dilutive. Positive: LigaChem cost-share and low-double-digit royalty structure on SIM0505 limit future spend if milestones achieved. Overall outlook hinges on early LNCB74 data by 4Q-25.

TL;DR: Balance-sheet erosion outweighs pipeline milestones鈥攕tock remains speculative.

Asset base fell 41% in six months while liabilities stayed flat, compressing equity to sub-$30 m. With mezzanine shares now permanent equity, float is still thin, limiting liquidity for institutional positions. Option overhang (855 k pre-split options) further pressures future cap structure. The company needs either a lucrative partnership or ~$50-60 m equity raise within 12 months; current biotech tape suggests unfavorable terms. Near-term catalysts (LNCB74 cohort data, first SIM0505 dosing) may drive volatility but are unlikely to unlock significant value before cash deadline. Risk-reward skews negative without a financing path.

Il 10-Q del secondo trimestre 2025 di NextCure evidenzia un netto peggioramento della liquidit脿 e perdite maggiori causate da un nuovo accordo di licenza. La liquidit脿 e gli equivalenti sono scesi a 4,9 milioni di dollari (-82%) e i titoli negoziabili a 30,4 milioni di dollari, lasciando 35,3 milioni di dollari disponibili rispetto ai 68,6 milioni di fine 2024. La direzione prevede che questi fondi copriranno le operazioni solo fino a met脿 2026 e dichiara un grave dubbio sulla continuit脿 aziendale.

Le spese operative sono aumentate del 65% su base annua, raggiungendo 27,3 milioni di dollari. La R&S 猫 raddoppiata a 24,1 milioni, principalmente a causa di un costo anticipato di 17 milioni di dollari per ricerca e sviluppo I-PR&D legato alla licenza SIM0505 ADC da Zaiming di giugno 2025. Le spese generali e amministrative sono diminuite del 22% a 3,2 milioni dopo una ristrutturazione nel 2024. La perdita netta del secondo trimestre si 猫 ampliata a 26,8 milioni (-11,29 dollari per azione) rispetto a 15,4 milioni (-6,61 dollari per azione) dell鈥檃nno precedente; la perdita del primo semestre 猫 di 37,8 milioni.

L鈥檃zienda ha raccolto solo 2 milioni tramite un collocamento privato (338,6 mila azioni a 5,904 dollari), classificato come capitale mezzanino fino alla registrazione presso la SEC (completata il 29 luglio 2025). Un split inverso 1-per-12 efficace dal 14 luglio 2025 ha ripristinato la conformit脿 al prezzo minimo di offerta Nasdaq, lasciando 2,68 milioni di azioni in circolazione al 4 agosto 2025.

Pipeline: La fase 1 dell鈥橝DC B7-H4 LNCB74 ha superato il terzo gruppo di pazienti e prevede di integrare nuovi gruppi nella seconda met脿 del 2025 con risultati di prova di concetto nella prima met脿 del 2026. L鈥橧ND di SIM0505 猫 stato trasferito dal partner; il primo paziente negli Stati Uniti 猫 atteso nel terzo trimestre 2025. La collaborazione per la condivisione dei costi con LigaChem ha generato un credito di 1 milione di dollari.

Elementi chiave del bilancio (giugno 2025 vs dicembre 2024):

  • Attivit脿 totali: 47,7 milioni di dollari vs 80,9 milioni
  • Perdita accumulata: 417,9 milioni (era 380,1 milioni)
  • Patrimonio netto: 29,6 milioni vs 65,5 milioni
In assenza di partnership o nuovi finanziamenti, appaiono probabili ulteriori diluizioni o ritardi nei programmi.

El informe 10-Q del segundo trimestre de 2025 de NextCure muestra un marcado deterioro en la liquidez y mayores p茅rdidas impulsadas por un nuevo acuerdo de licencia. El efectivo y equivalentes cayeron a 4,9 millones de d贸lares (-82%) y los valores negociables a 30,4 millones, dejando 35,3 millones disponibles frente a 68,6 millones al cierre de 2024. La direcci贸n espera que estos fondos financien las operaciones solo hasta mediados de 2026 y declara dudas sustanciales sobre la continuidad operativa.

Los gastos operativos aumentaron un 65% interanual a 27,3 millones. I+D se duplic贸 a 24,1 millones, principalmente debido a un cargo inicial de 17 millones de d贸lares por investigaci贸n y desarrollo I-PR&D relacionado con la licencia SIM0505 ADC de junio de 2025 de Zaiming. Los gastos generales y administrativos cayeron un 22% a 3,2 millones tras una reestructuraci贸n en 2024. La p茅rdida neta del segundo trimestre se ampli贸 a 26,8 millones (-11,29 d贸lares por acci贸n) desde 15,4 millones (-6,61 d贸lares por acci贸n) un a帽o antes; la p茅rdida del primer semestre es de 37,8 millones.

La compa帽铆a recaud贸 solo 2 millones mediante una colocaci贸n privada (338,6 mil acciones a 5,904 d贸lares), clasificada como capital mezzanine hasta la inscripci贸n en la SEC (completada el 29 de julio de 2025). Un split inverso de 1 por 12 efectivo el 14 de julio de 2025 restaur贸 el cumplimiento del precio m铆nimo en Nasdaq, dejando 2,68 millones de acciones en circulaci贸n al 4 de agosto de 2025.

Pipeline: La fase 1 del ADC B7-H4 LNCB74 super贸 la cohorte 3 y espera completar cohortes adicionales en la segunda mitad de 2025 con resultados de prueba de concepto en la primera mitad de 2026. El IND de SIM0505 fue transferido del socio; se espera el primer paciente en EE.UU. en el tercer trimestre de 2025. La colaboraci贸n de ADC con LigaChem para compartir costos gener贸 una cuenta por cobrar de 1 mill贸n.

Elementos clave del balance (junio 2025 vs diciembre 2024):

  • Activos totales: 47,7 millones vs 80,9 millones
  • D茅ficit acumulado: 417,9 millones (antes 380,1 millones)
  • Patrimonio: 29,6 millones vs 65,5 millones
Sin asociaciones o financiamiento, parecen probables nuevas diluciones o retrasos en los programas.

NextCure鞚� 2025雲� 2攵勱赴 10-Q 氤搓碃靹滊姅 鞁犼窚 霛检澊靹犾姢 瓿勳暯鞙茧 鞚疙暣 鞙犽彊靹� 旮夑皭瓿� 靻愳嫟 歃濌皜毳� 氤挫棳欷嶋媹雼�. 順勱笀 氚� 順勱笀靹� 鞛愳偘鞚� 490毵� 雼煬(-82%)搿� 臧愳唽頄堦碃, 鞁滌灔靹� 歃濌秾鞚� 3,040毵� 雼煬搿� 欷勳柎 2024雲� 毵� 6,860毵� 雼煬鞐愳劀 3,530毵� 雼煬毵� 靷毄 臧�電ロ晿瓴� 霅橃棃鞀惦媹雼�. 瓴届榿歆勳潃 鞚� 鞛愱笀鞚� 2026雲� 欷戨皹旯岇 鞖挫榿 鞛愱笀鞙茧 於╇秳頃� 瓴冹溂搿� 鞓堨儊頃橂┌, 旮办梾 臁挫啀鞐� 雽�頃� 欷戨寑頃� 鞚橂鞚� 響滊獏頄堨姷雼堧嫟.

鞓侅梾牍勳毄鞚� 鞝勲厔 雽�牍� 65% 歃濌皜頃� 2,730毵� 雼煬毳� 旮半頄堨姷雼堧嫟. 鞐瓣惮臧滊皽牍勲姅 欤茧 2025雲� 6鞗� Zaiming鞙茧攵�韯� 氚涭潃 SIM0505 ADC 霛检澊靹犾姢 甏�霠� 1,700毵� 雼煬鞚� 靹犼笁 I-PR&D 牍勳毄鞙茧 鞚疙暣 2,410毵� 雼煬搿� 霊� 氚瓣皜 霅橃棃鞀惦媹雼�. 鞚茧皹甏�毽箘電� 2024雲� 甑“臁办爼 鞚错泟 22% 臧愳唽頃� 320毵� 雼煬毳� 旮半頄堨姷雼堧嫟. 2攵勱赴 靾滌啇鞁れ潃 2,680毵� 雼煬(-欤茧嫻 11.29雼煬)搿� 鞝勲厔 霃欔赴 1,540毵� 雼煬(-欤茧嫻 6.61雼煬)鞐愳劀 頇曤寑霅橃棃鞙茧┌, 靸侂皹旮� 靻愳嫟鞚� 3,780毵� 雼煬鞛呺媹雼�.

須岇偓電� 靷 氚滍枆鞚� 韱淀暣 200毵� 雼煬(欤茧嫻 5.904雼煬鞐� 33毵� 8,600欤�)毵� 臁半嫭頄堨溂氅�, SEC 霌彪 鞕勲(2025雲� 7鞗� 29鞚�) 鞝勱箤歆� 氅旍瀽雼� 鞛愲掣鞙茧 攵勲霅橃棃鞀惦媹雼�. 2025雲� 7鞗� 14鞚� 氚滍毃霅� 1雽� 12 鞐硲頃�鞙茧 雮橃姢雼� 鞛呾鞍臧� 旮办鞚� 須岆车頄堨溂氅�, 2025雲� 8鞗� 4鞚� 旮办 氚滍枆 欤检嫕 靾橂姅 268毵� 欤检瀰雼堧嫟.

韺岇澊頂勲澕鞚�: 1靸� B7-H4 ADC LNCB74電� 3氩堨Ц 旖旐樃韸鸽ゼ 韱店臣頄堨溂氅�, 2025雲� 頃橂皹旮办棎 於旉皜 旖旐樃韸鸽ゼ 毂勳毎瓿� 2026雲� 靸侂皹旮办棎 臧滊厫 歃濍獏 瓴瓣臣毳� 旮半寑頃橁碃 鞛堨姷雼堧嫟. SIM0505 IND電� 韺岉姼雱堧攵�韯� 鞚挫爠霅橃棃鞙茧┌, 氙戈淡 觳� 頇橃瀽電� 2025雲� 3攵勱赴鞐� 鞓堨儊霅╇媹雼�. LigaChem瓿检潣 牍勳毄 攵勲嫶 ADC 順戨牓鞙茧 100毵� 雼煬鞚� 氙胳垬旮堨澊 氚滌儩頄堨姷雼堧嫟.

欤检殧 鞛 頃(2025雲� 6鞗� vs 2024雲� 12鞗�):

  • 齑� 鞛愳偘: 4,770毵� 雼煬 vs 8,090毵� 雼煬
  • 雸勳爜 鞝侅瀽: 4鞏� 1,790毵� 雼煬 (鞚挫爠 3鞏� 8,010毵� 雼煬)
  • 鞛愲掣: 2,960毵� 雼煬 vs 6,550毵� 雼煬
韺岉姼雱堨嫮鞚措倶 於旉皜 鞛愱笀 臁半嫭 鞐嗢澊電� 於旉皜 頋劃鞚措倶 頂勲攴鸽灗 歆�鞐办澊 鞓堨儊霅╇媹雼�.

Le rapport 10-Q du deuxi猫me trimestre 2025 de NextCure r茅v猫le une forte d茅t茅rioration de la liquidit茅 et des pertes accrues dues 脿 un nouvel accord de licence. La tr茅sorerie et les 茅quivalents ont chut茅 脿 4,9 millions de dollars (-82 %) et les titres n茅gociables 脿 30,4 millions, laissant 35,3 millions disponibles contre 68,6 millions 脿 la fin 2024. La direction pr茅voit que ces fonds ne financeront les op茅rations que jusqu'脿 la mi-2026 et exprime un doute important sur la continuit茅 d鈥檈xploitation.

Les d茅penses d鈥檈xploitation ont bondi de 65 % en glissement annuel 脿 27,3 millions. La R&D a doubl茅 脿 24,1 millions, principalement en raison d鈥檜ne charge initiale de 17 millions de dollars pour I-PR&D li茅e 脿 la licence ADC SIM0505 de juin 2025 accord茅e par Zaiming. Les frais g茅n茅raux et administratifs ont diminu茅 de 22 % 脿 3,2 millions apr猫s une restructuration en 2024. La perte nette du T2 s鈥檈st creus茅e 脿 26,8 millions (-11,29 $ par action) contre 15,4 millions (-6,61 $ par action) un an plus t么t ; la perte du premier semestre est de 37,8 millions.

La soci茅t茅 n鈥檃 lev茅 que 2 millions via un placement priv茅 (338,6 k actions 脿 5,904 $), class茅 en quasi-fonds propres jusqu鈥櫭� l鈥檈nregistrement aupr猫s de la SEC (achev茅 le 29 juillet 2025). Un split invers茅 1 pour 12 effectif au 14 juillet 2025 a r茅tabli la conformit茅 au prix plancher Nasdaq, laissant 2,68 millions d鈥檃ctions en circulation au 4 ao没t 2025.

Pipeline : La phase 1 de l鈥橝DC B7-H4 LNCB74 a franchi la cohorte 3 et pr茅voit de compl茅ter les cohortes au second semestre 2025 avec un r茅sultat de preuve de concept au premier semestre 2026. L鈥橧ND SIM0505 a 茅t茅 transf茅r茅e du partenaire ; le premier patient am茅ricain est attendu au T3 2025. La collaboration ADC en partage de co没ts avec LigaChem a g茅n茅r茅 une cr茅ance de 1 million.

Principaux 茅l茅ments du bilan (juin 2025 vs d茅cembre 2024) :

  • Actifs totaux : 47,7 M$ contre 80,9 M$
  • D茅ficit accumul茅 : 417,9 M$ (contre 380,1 M$)
  • Capitaux propres : 29,6 M$ contre 65,5 M$
En l'absence de partenariats ou de financements, de nouvelles dilutions ou des retards dans les programmes semblent probables.

Der 10-Q-Bericht von NextCure f眉r das zweite Quartal 2025 zeigt eine deutliche Verschlechterung der Liquidit盲t und h枚here Verluste, verursacht durch einen neuen Lizenzvertrag. Zahlungsmittel und 脛quivalente fielen auf 4,9 Mio. USD (-82%) und marktf盲hige Wertpapiere auf 30,4 Mio. USD, womit 35,3 Mio. USD verf眉gbar sind gegen眉ber 68,6 Mio. USD zum Jahresende 2024. Das Management erwartet, dass diese Mittel nur bis Mitte 2026 f眉r den Betrieb ausreichen und 盲u脽ert .

Die Betriebsausgaben stiegen im Jahresvergleich um 65 % auf 27,3 Mio. USD. Die F&E-Kosten verdoppelten sich auf 24,1 Mio. USD, haupts盲chlich aufgrund einer 17 Mio. USD Vorab-/I-PR&D-Aufwendung f眉r die im Juni 2025 von Zaiming erworbene SIM0505 ADC-Lizenz. Die allgemeinen Verwaltungskosten sanken nach einer Umstrukturierung 2024 um 22 % auf 3,2 Mio. USD. Der Nettoverlust im 2. Quartal weitete sich auf 26,8 Mio. USD (-11,29 USD je Aktie) aus, verglichen mit 15,4 Mio. USD (-6,61 USD je Aktie) im Vorjahr; der Verlust im ersten Halbjahr betr盲gt 37,8 Mio. USD.

Das Unternehmen erzielte nur 2 Mio. USD durch eine Privatplatzierung (338.600 Aktien zu 5,904 USD), die bis zur SEC-Registrierung (abgeschlossen am 29. Juli 2025) als Mezzanine-Kapital klassifiziert wurde. Ein 1-zu-12 Reverse Split, wirksam ab dem 14. Juli 2025, stellte die Einhaltung der Nasdaq-Notierungsanforderungen wieder her und lie脽 am 4. August 2025 2,68 Mio. ausstehende Aktien verbleiben.

Pipeline: Die Phase-1-Studie des B7-H4 ADC LNCB74 hat Kohorte 3 abgeschlossen und plant, im zweiten Halbjahr 2025 weitere Kohorten zu erg盲nzen, mit einem Proof-of-Concept-Ergebnis in der ersten H盲lfte 2026. Die IND f眉r SIM0505 wurde vom Partner 眉bertragen; der erste US-Patient wird im 3. Quartal 2025 erwartet. Die ADC-Kostenbeteiligungs-Kooperation mit LigaChem brachte eine Forderung 眉ber 1 Mio. USD ein.

Wichtige Bilanzposten (Juni 2025 vs. Dezember 2024):

  • Gesamtverm枚gen: 47,7 Mio. USD vs. 80,9 Mio. USD
  • Kumuliertes Defizit: 417,9 Mio. USD (vorher 380,1 Mio. USD)
  • Eigenkapital: 29,6 Mio. USD vs. 65,5 Mio. USD
Ohne Partnerschaften oder Finanzierung erscheinen weitere Verw盲sserungen oder Programmverz枚gerungen wahrscheinlich.

falseQ22025--12-31000166105923375160023338960http://fasb.org/us-gaap/2025#PrepaidExpenseAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2025#PrepaidExpenseAndOtherAssetsCurrent000000000.080.08P4Y9M0.080.080001661059us-gaap:CommonStockMember2024-01-012024-03-310001661059us-gaap:CommonStockMember2025-04-012025-06-300001661059us-gaap:CommonStockMember2024-04-012024-06-300001661059us-gaap:RetainedEarningsMember2025-06-300001661059us-gaap:AdditionalPaidInCapitalMember2025-06-300001661059us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-300001661059us-gaap:RetainedEarningsMember2025-03-310001661059us-gaap:AdditionalPaidInCapitalMember2025-03-3100016610592025-03-310001661059us-gaap:RetainedEarningsMember2024-12-310001661059us-gaap:AdditionalPaidInCapitalMember2024-12-310001661059us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001661059us-gaap:RetainedEarningsMember2024-06-300001661059us-gaap:AdditionalPaidInCapitalMember2024-06-300001661059us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001661059us-gaap:RetainedEarningsMember2024-03-310001661059us-gaap:AdditionalPaidInCapitalMember2024-03-310001661059us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-3100016610592024-03-310001661059us-gaap:RetainedEarningsMember2023-12-310001661059us-gaap:AdditionalPaidInCapitalMember2023-12-310001661059us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001661059srt:MaximumMember2025-01-310001661059nxtc:EmployeeStockPurchase2019PlanMember2025-01-012025-06-3000016610592024-01-012024-12-310001661059us-gaap:EmployeeSeveranceMember2025-06-300001661059us-gaap:EmployeeSeveranceMember2024-03-192024-03-190001661059us-gaap:EmployeeSeveranceMember2024-04-012024-06-300001661059us-gaap:RetainedEarningsMember2025-04-012025-06-300001661059us-gaap:RetainedEarningsMember2025-01-012025-03-310001661059us-gaap:RetainedEarningsMember2024-04-012024-06-300001661059us-gaap:RetainedEarningsMember2024-01-012024-03-310001661059us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2025-06-300001661059us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:CorporateDebtSecuritiesMember2025-06-300001661059us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2025-06-300001661059us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:CorporateDebtSecuritiesMember2025-06-300001661059us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2024-12-310001661059us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310001661059us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2024-12-310001661059us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310001661059us-gaap:CommonStockMember2025-06-300001661059us-gaap:CommonStockMember2025-03-310001661059us-gaap:CommonStockMember2024-12-310001661059us-gaap:CommonStockMember2024-06-300001661059us-gaap:CommonStockMember2024-03-310001661059us-gaap:CommonStockMember2023-12-310001661059nxtc:OmnibusIncentive2019PlanMember2025-06-300001661059nxtc:EmployeeStockPurchase2019PlanMember2025-06-3000016610592024-06-3000016610592023-12-310001661059us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:MoneyMarketFundsMember2025-06-300001661059us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:MoneyMarketFundsMember2025-06-300001661059us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:MoneyMarketFundsMember2024-12-310001661059us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:MoneyMarketFundsMember2024-12-310001661059nxtc:USTreasurySecuritiesAndUSGovernmentCorporationsAndAgenciesSecuritiesMember2025-06-300001661059us-gaap:CorporateDebtSecuritiesMember2025-06-300001661059us-gaap:CorporateDebtSecuritiesMember2024-12-310001661059nxtc:USTreasurySecuritiesAndUSGovernmentCorporationsAndAgenciesSecuritiesMember2024-12-310001661059us-gaap:EmployeeStockOptionMember2025-04-012025-06-300001661059us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001661059us-gaap:ResearchAndDevelopmentExpenseMember2025-04-012025-06-300001661059us-gaap:GeneralAndAdministrativeExpenseMember2025-04-012025-06-300001661059us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-06-300001661059us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-06-300001661059us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300001661059us-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-06-300001661059us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300001661059us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-06-300001661059us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-300001661059us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001661059us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001661059us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001661059us-gaap:SubsequentEventMember2025-07-142025-07-140001661059nxtc:OmnibusIncentive2019PlanMember2019-05-032019-05-030001661059nxtc:OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember2025-01-012025-06-300001661059us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-012025-06-300001661059us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-3100016610592025-01-012025-03-310001661059us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-3000016610592024-04-012024-06-300001661059us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-3100016610592024-01-012024-03-310001661059nxtc:LegochemBiosciencesMembernxtc:ResearchAndDevelopmentCollaborativeAgreementMember2022-11-012022-11-300001661059us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2025-06-300001661059us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2025-06-300001661059us-gaap:EstimateOfFairValueFairValueDisclosureMember2025-06-300001661059us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-12-310001661059us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-12-310001661059us-gaap:EstimateOfFairValueFairValueDisclosureMember2024-12-310001661059nxtc:SingleReportingSegmentMember2025-06-300001661059srt:MaximumMembernxtc:UponAchievingDevelopmentAndRegulatoryMilestoneOfZaimingProductMember2025-06-130001661059srt:MaximumMembernxtc:UponAchievingDevelopmentAndRegulatoryMilestoneOfNextcureProductMember2025-06-130001661059srt:MaximumMembernxtc:UponAchievingCommercialSalesBasedMilestoneMember2025-06-1300016610592025-06-132025-06-1300016610592025-06-130001661059nxtc:SingleReportingSegmentMember2025-04-012025-06-300001661059nxtc:SingleReportingSegmentMember2025-01-012025-06-300001661059nxtc:SingleReportingSegmentMember2024-04-012024-06-300001661059nxtc:SingleReportingSegmentMember2024-01-012024-06-3000016610592024-01-012024-06-3000016610592025-01-012025-01-310001661059nxtc:UponInitiationOfFirstPhase2ClinicalTrialForSim0505Member2025-06-130001661059nxtc:LegochemBiosciencesMembernxtc:ResearchAndDevelopmentCollaborativeAgreementMember2025-04-012025-06-300001661059nxtc:ResearchAndDevelopmentCollaborativeAgreementMember2025-06-300001661059nxtc:LegochemBiosciencesMembernxtc:ResearchAndDevelopmentCollaborativeAgreementMember2022-11-300001661059nxtc:LegochemBiosciencesMembernxtc:ResearchAndDevelopmentCollaborativeAgreementMember2025-06-3000016610592025-06-3000016610592024-12-3100016610592025-04-012025-06-3000016610592025-08-0400016610592025-01-012025-06-30xbrli:sharesiso4217:USDxbrli:purenxtc:itemiso4217:USDxbrli:sharesnxtc:segment

Table of Contents

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

​

☒

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

​

For the quarterly period ended June 30, 2025

​

or

​

☐

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

​

For the transition period from                    to                   .

​

Commission File Number: 001-38905

NextCure, Inc.

(Exact name of registrant as specified in its charter)

Delaware

47-5231247

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

​

​

9000 Virginia Manor Road, Suite 200
Beltsville, Maryland

20705

(Address of principal executive offices)

(Zip Code)

​

(240) 399-4900

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class

Trading Symbol(s)

Name of each exchange on which registered:

Common Stock, $0.001 par value per share

NXTC

Nasdaq Global Select Market

​

Indicate by check mark whether the registrant:  (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

​

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

​

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

​

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer ☒

Smaller reporting company ☒

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

​

As of August 4, 2025, the registrant had 2,676,110 shares of common stock, par value $0.001 per share, issued and outstanding.

​

​

​

​

Table of Contents

NextCure, Inc.

Form 10-Q

For the Quarter Ended June 30, 2025

​

TABLE OF CONTENTS

​

​

​

​

​

Page

PART I. FINANCIAL INFORMATION

Item 1.

Financial Statements

1

​

Condensed Balance Sheets as of June 30, 2025 (unaudited) and December 31, 2024

1

​

Unaudited Condensed Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2025 and 2024

2

​

Unaudited Condensed Statements of Stockholders’ Equity for the Three and Six Months Ended June 30, 2025 and 2024

3

​

Unaudited Condensed Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024

4

​

Notes to Unaudited Condensed Financial Statements

5

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

16

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

25

Item 4.

Controls and Procedures

25

Part II. OTHER INFORMATION

Item 1.

Legal Proceedings

26

Item 1A.

Risk Factors

26

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

26

Item 3.

Defaults Upon Senior Securities

26

Item 4.

Mine Safety Disclosures

27

Item 5.

Other Information

27

Item 6.

Exhibits

28

SIGNATURES

29

​

​

​

​

i

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

NEXTCURE, INC.

CONDENSED BALANCE SHEETS

( in thousands, except share and per share amounts)

​

​

​

​

​

​

​

​

​

​

June 30, 2025

    

December 31, 

​

    

(unaudited)

    

2024

Assets

 

​

​

​

  

Current assets:

 

​

​

​

​

  

Cash and cash equivalents

​

$

4,892

​

$

27,727

Marketable securities

​

​

30,416

​

​

40,894

Prepaid expenses and other current assets

​

 

4,707

​

 

3,186

Total current assets

​

 

40,015

​

 

71,807

Property and equipment, net

​

 

4,171

​

 

5,458

Right of use assets

​

​

2,948

​

​

3,263

Other assets

​

 

555

​

 

332

Total assets

​

$

47,689

​

$

80,860

Liabilities and Stockholders’ Equity

​

 

  

​

 

  

Current liabilities:

​

 

  

​

 

  

Accounts payable

​

$

2,544

​

$

5,353

Accrued liabilities and other liabilities

​

 

8,237

​

 

4,221

Total current liabilities

​

 

10,781

​

 

9,574

Lease liabilities, long term

​

​

4,666

​

​

5,153

Other long-term liabilities

​

 

596

​

 

661

Total liabilities

​

 

16,043

​

 

15,388

Mezzanine equity:

​

​

​

​

​

​

Common stock, par value of $0.001 per share; 100,000,000 shares authorized at June 30, 2025 and December 31, 2024; 338,636 and 0 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively

​

​

2,000

​

​

—

Stockholders’ equity:

​

 

  

​

 

  

Preferred stock, par value of $0.001 per share; 10,000,000 shares authorized at June 30, 2025 and December 31, 2024; No shares issued and outstanding at June 30, 2025 and December 31, 2024

​

​

—

​

​

—

Common stock, par value of $0.001 per share; 100,000,000 shares authorized at June 30, 2025 and December 31, 2024; 2,337,516 and 2,333,896 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively

​

 

2

​

 

2

Additional paid-in capital

​

 

447,571

​

 

445,602

Accumulated other comprehensive (loss) income

​

​

(7)

​

​

4

Accumulated deficit

​

 

(417,920)

​

 

(380,136)

Total stockholders’ equity

​

 

29,646

​

 

65,472

Total liabilities and stockholders’ equity

​

$

47,689

​

$

80,860

​

​

The accompanying notes are an integral part of these unaudited condensed financial statements.

​

1

Table of Contents

NEXTCURE, INC.

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited, in thousands, except share and per share amounts)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Six Months Ended

​

​

​

June 30, 

​

June 30, 

​

​

    

2025

    

2024

    

2025

    

2024

​

Operating expenses:

​

​

​

​

​

​

​

​

​

​

​

​

​

Research and development

​

$

24,091

​

$

12,418

​

$

31,987

​

$

23,816

​

General and administrative

​

 

3,201

​

​

4,076

​

​

6,927

​

​

8,440

​

Restructuring and asset impairment charges

​

​

—

​

​

—

​

​

—

​

​

2,542

​

Total operating expenses

​

 

27,292

​

 

16,494

​

 

38,914

​

 

34,798

​

Loss from operations

​

 

(27,292)

​

 

(16,494)

​

 

(38,914)

​

 

(34,798)

​

Other income, net

​

 

484

​

 

1,090

​

 

1,130

​

 

2,287

​

Net loss

​

$

(26,808)

​

$

(15,404)

​

$

(37,784)

​

$

(32,511)

​

Net loss per common share - basic and diluted

​

$

(11.29)

​

$

(6.61)

​

$

(16.05)

​

$

(13.96)

​

Weighted-average shares outstanding - basic and diluted

​

​

2,374,729

​

​

2,331,062

​

​

2,354,425

​

​

2,328,157

​

Comprehensive loss:

​

​

​

​

​

​

​

​

​

​

​

​

​

Net loss

​

$

(26,808)

​

$

(15,404)

​

$

(37,784)

​

$

(32,511)

​

Unrealized (loss) gain on marketable securities

​

​

(7)

​

​

96

​

​

(11)

​

​

136

​

Total comprehensive loss

​

$

(26,815)

​

$

(15,308)

​

$

(37,795)

​

$

(32,375)

​

​

The accompanying notes are an integral part of these unaudited condensed financial statements.

​

​

​

2

Table of Contents

​

NEXTCURE, INC.

CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY

(unaudited, in thousands, except share data)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Six Months Ended June 30, 2025

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Stockholders’ Equity

​

​

​

​

​

​

​

Additional

​

Accumulated Other

​

​

​

​

​

 

​

​

Common Stock

​

Paid-in

​

Comprehensive

​

Accumulated

​

Stockholders’

​

​

Shares

​

Amount

​

Capital

​

(Loss) Income

​

Deficit

​

Equity

Balance as of December 31, 2024

 

2,333,896

​

$

2

​

$

445,602

​

$

4

​

$

(380,136)

​

$

65,472

Stock-based compensation

​

—

​

​

—

​

​

1,363

​

​

—

​

​

—

​

​

1,363

Unrealized loss on marketable securities, net of tax

​

—

​

​

—

​

​

—

​

​

(4)

​

​

—

​

​

(4)

Net loss

​

—

​

​

—

​

​

—

​

​

—

​

​

(10,976)

​

​

(10,976)

Balance as of March 31, 2025

​

2,333,896

​

$

2

​

$

446,965

​

$

—

​

$

(391,112)

​

$

55,855

Stock-based compensation

​

—

​

​

—

​

​

587

​

​

—

​

​

—

​

​

587

Issuance of shares under ESPP

​

3,620

​

​

—

​

​

19

​

​

—

​

​

—

​

​

19

Unrealized loss on marketable securities, net of tax $0

​

—

​

​

—

​

​

—

​

​

(7)

​

​

—

​

​

(7)

Net loss

​

—

​

​

—

​

​

—

​

​

—

​

​

(26,808)

​

​

(26,808)

Balance as of June 30, 2025

​

2,337,516

​

$

2

​

$

447,571

​

$

(7)

​

$

(417,920)

​

$

29,646

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Six Months Ended June 30, 2024

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Stockholders’ Equity

​

​

​

​

​

​

​

Additional

​

Accumulated Other

​

​

​

​

​

 

​

​

Common Stock

​

Paid-in

​

Comprehensive

​

Accumulated

​

Stockholders’

​

​

Shares

​

Amount

​

Capital

​

(Loss) Income

​

Deficit

​

Equity

Balance as of December 31, 2023

 

2,325,252

​

$

2

​

$

439,123

​

$

(222)

​

$

(324,482)

​

$

114,421

Stock-based compensation

​

—

​

​

—

​

​

1,693

​

​

—

​

​

—

​

​

1,693

Exercise of stock options

​

50

​

​

—

​

​

1

​

​

—

​

​

—

​

​

1

Unrealized gain on marketable securities, net of tax

​

—

​

​

—

​

​

—

​

​

40

​

​

—

​

​

40

Net loss

 

—

​

​

—

​

​

—

​

​

—

​

​

(17,107)

​

​

(17,107)

Balance as of March 31, 2024

​

2,325,302

​

$

2

​

$

440,817

​

$

(182)

​

$

(341,589)

​

$

99,048

Stock-based compensation

​

—

​

​

—

​

​

1,594

​

​

—

​

​

—

​

​

1,594

Exercise of stock options

​

1,165

​

​

—

​

​

22

​

​

—

​

​

—

​

​

22

Issuance of shares under ESPP

​

3,423

​

​

—

​

​

46

​

​

—

​

​

—

​

​

46

Issuance of shares from at-the-market sales, net of expenses

​

1,429

​

​

—

​

​

39

​

​

—

​

​

—

​

​

39

Unrealized gain on marketable securities, net of tax $0

​

—

​

​

—

​

​

—

​

​

96

​

​

—

​

​

96

Net loss

 

—

​

​

—

​

​

—

​

​

—

​

​

(15,404)

​

​

(15,404)

Balance as of June 30, 2024

​

2,331,319

​

$

2

​

$

442,518

​

$

(86)

​

$

(356,993)

​

$

85,441

​

The accompanying notes are an integral part of these unaudited condensed financial statements.

​

3

Table of Contents

NEXTCURE, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(unaudited, in thousands)

​

​

​

​

​

​

​

​

​

​

Six Months Ended

​

​

June 30, 

​

    

2025

    

2024

Cash flows from operating activities:

 

​

  

​

​

  

Net loss

​

$

(37,784)

​

$

(32,511)

Adjustments to reconcile net loss to net cash used in operating activities:

​

 

​

​

​

​

Depreciation and amortization

​

 

1,287

​

​

1,491

Amortization of premiums and discounts on marketable securities

​

​

(386)

​

​

(614)

Stock-based compensation

​

 

1,951

​

​

3,287

Asset impairment

​

​

—

​

​

1,786

Noncash operating lease expense

​

​

288

​

​

284

Changes in operating assets and liabilities:

​

 

​

​

​

​

Prepaid expenses and other assets

​

 

(1,716)

​

​

365

Accounts payable

​

 

(2,809)

​

​

2,745

Accrued liabilities and other liabilities

​

 

4,016

​

​

1,204

Lease liabilities

​

​

(488)

​

​

(359)

Other long-term liabilities

​

​

(66)

​

​

(60)

Net cash used in operating activities

​

 

(35,707)

​

​

(22,382)

Cash flows from investing activities:

​

 

​

​

​

​

Sales and maturities of marketable securities

​

 

37,558

​

​

63,961

Purchases of marketable securities

​

​

(26,705)

​

​

(33,582)

Purchases of property and equipment

​

​

—

​

​

(338)

Net cash provided by investing activities

​

 

10,853

​

​

30,041

Cash flows from financing activities:

​

 

​

​

​

​

Proceeds from issuance of mezzanine equity

​

​

2,000

​

​

—

Net proceeds from at-the-market sales

​

​

—

​

​

39

Proceeds from exercise of stock options

​

​

—

​

​

22

Proceeds from shares issued under ESPP

​

​

19

​

​

46

Net cash provided by financing activities

​

 

2,019

​

​

107

Net increase (decrease) in cash and cash equivalents

​

 

(22,835)

​

​

7,766

Cash and cash equivalents – beginning of period

​

 

27,727

​

​

13,082

Cash and cash equivalents – end of period

​

$

4,892

​

$

20,848

Supplemental disclosures of cash flow information:

​

 

​

​

​

​

Cash paid for interest

​

$

32

​

$

37

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

The accompanying notes are an integral part of these unaudited condensed financial statements.

​

​

​

4

Table of Contents

1. Nature of the Business

Organization

NextCure, Inc. (“NextCure” the “Company,” “we,” “us,” or “our”) was incorporated in Delaware in September 2015 and is headquartered in Beltsville, Maryland. The Company is a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The Company focuses on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Since inception, the Company has devoted substantially all of its efforts and financial resources to discovery, research and development activities for the Company’s product candidates, identifying business development opportunities, raising capital and securing intellectual property rights related to the Company’s product candidates.

Reverse Stock Split

On July 14, 2025, the Company effectuated a one-for-twelve (1:12) reverse stock split of its outstanding shares of common stock (the “Reverse Stock Split”). In connection with the Reverse Stock Split, every twelve shares of the Company’s common stock issued and outstanding as of July 14, 2025 were automatically converted into one share of the Company’s common stock. No fractional shares were issued in connection with the Reverse Stock Split. The Company’s stockholders received the cash value equal to the fraction to which the stockholder would otherwise be entitled, multiplied by the closing price of the common stock, as reported by The Nasdaq Stock Market, LLC (“Nasdaq”), on the last trading day prior to the effective date of the Reverse Stock Split. All share and per share data for all periods presented in the accompanying financial statements and the related disclosures in this Quarterly Report on Form 10-Q have been adjusted retrospectively to reflect the Reverse Stock Split. The number of authorized shares of common stock and the par value per share remains unchanged.

​

Liquidity

The Company has not generated any revenue to date from product sales and does not expect to generate any revenues from product sales in the foreseeable future. Through June 30, 2025, the Company has funded its operations primarily with proceeds from public offerings of its common stock, private placements of its preferred stock and upfront fees received under the Company’s former agreement with Eli Lilly and Company, which was terminated in March 2020. The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future.

As of June 30, 2025, the Company had cash, cash equivalents and marketable securities of $35.3 million. The Company believes that its existing cash, cash equivalents and marketable securities will be sufficient to fund its planned operations for at least the next twelve months from the issuance of these financial statements.  See Note 2, Summary of Significant Accounting Policies for a futher assessment of liquidity.

2. Summary of Significant Accounting Policies

There have been no material changes to the significant accounting policies previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 (the “Annual Report”).

Basis of Presentation

The unaudited condensed financial statements include the accounts of the Company and have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto in the Annual Report.

5

Table of Contents

Unaudited Financial Information

In the opinion of management, the information furnished reflects certain adjustments, all which are of a normal and recurring nature and are necessary for a fair presentation of the Company’s financial position as of the reported balance sheet date and of the Company’s results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period.

Liquidity and Going Concern

The Company has incurred net losses and negative cash flows from operations since its inception, has an accumulated deficit of $417.9 million as of June 30, 2025 and anticipates continuing to incur net losses for the foreseeable future. Under the Company's current plan, management believes its cash and cash equivalents and marketable securities of $35.3 million as of June 30, 2025 will be sufficient to fund the Company's operations into mid-2026.  However, the Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the issuance of the condensed financial statements.

As a result, the Company will be required to raise additional capital by partnering, selling equity, or other means. There can be no assurance as to whether partnering efforts will be successful or whether additional financing will be available on terms acceptable to the Company, if at all. If sufficient funds on acceptable terms are not available when needed, it would have a negative impact on the Company’s financial condition and could force the Company to delay, limit, reduce, or terminate product development or future commercialization efforts or grant rights to develop and market product candidates that the Company would otherwise plan to develop and market itself.

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The accompanying financial statements do not reflect any adjustments relating to the recoverability and reclassifications of assets and liabilities that might be necessary if the Company is unable to continue as a going concern.

The Company intends to raise additional capital to continue the advancement of its programs. In the near term, the Company's primary uses of cash will be to fund the completion of key milestones for clinical programs and to fund its operations, including research and development activities and employee salaries. This includes significant costs relating to clinical trials of the Company's product candidates. The Company's planned uses of cash in the long term will be similar as the Company advances its research and development activities and pays employee salaries. Most pharmaceutical products require larger clinical trials as development progresses, and the Company expects its funding requirements to grow with the advancement of its programs. The Company's long-term funding requirements will depend on many factors, which are uncertain but include its portfolio prioritization decisions and the success of its collaborations. In turn, the Company's ability to raise additional capital will depend on the general economic environment in which it operates and its ability to achieve key milestones.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities as of the date of the condensed financial statements, and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material.

Recently Issued Accounting Pronouncements

The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”). All other ASUs issued subsequent to the filing of the Company’s

6

Table of Contents

Annual Report were assessed and determined to be either inapplicable or not expected to have a material impact on the Company’s financial position or results of operations.

​

​

3. Marketable Securities

Marketable securities consist of the following:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

June 30, 2025

​

​

​

​

​

Gross

​

Gross

​

​

​

​

​

Amortized

​

Unrealized

​

Unrealized

​

Estimated

(in thousands)

    

Cost

    

Gain

    

Loss

    

Fair Value

Corporate bonds

​

$

22,944

​

$

5

​

$

(11)

​

$

22,938

U.S. Treasury and Government agencies

​

​

7,479

​

​

—

​

​

(1)

​

​

7,478

Total

​

$

30,423

​

$

5

​

$

(12)

​

$

30,416

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

December 31, 2024

​

​

​

​

​

Gross

​

Gross

​

​

​

​

​

Amortized

​

Unrealized

​

Unrealized

​

Estimated

(in thousands)

    

Cost

    

Gain

    

Loss

    

Fair Value

Corporate bonds

​

$

32,515

​

$

22

​

$

(20)

​

$

32,517

U.S. Treasury and Government agencies

​

​

8,375

​

​

2

​

​

—

​

​

8,377

Total

​

$

40,890

​

$

24

​

$

(20)

​

$

40,894

​

​

The Company uses the specific identification method when calculating realized gains and losses. The Company did not realize any gains or losses on available-for-sale securities for the three and six months ended June 30, 2025 and 2024.

The Company reviewed all investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. As of June 30, 2025, the Company had investments with a total fair market value of $19.4 million in an immaterial unrealized loss position, of which none were in a continuous unrealized loss position for more than twelve months. The Company analyzed the unrealized losses and determined that market conditions were the primary factor driving these changes, and such unrealized losses are temporary as the Company anticipates a full recovery of the amortized cost basis of these securities at maturity. After analyzing the securities in an unrealized loss position, the portion of these losses that relates to changes in credit quality is insignificant. The Company does not intend to sell these securities, nor is it more likely than not that the Company will be required to sell them prior to the end of their contractual terms. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk.

The following table summarizes maturities of the Company’s investments available-for-sale as of June 30, 2025:

​

​

​

​

​

​

​

​

​

June 30, 2025

​

​

​

​

​

Fair

(in thousands)

    

Cost

    

Value

Maturities:

​

​

​

​

​

​

Within 1 year

​

$

25,674

​

$

25,666

Over 1 year

​

 

4,749

​

 

4,750

Total investments available-for-sale

​

$

30,423

​

$

30,416

​

The Company has elected to report interest receivable from its marketable securities with prepaid expenses and other current assets on its balance sheet.  Interest receivable included in prepaid expenses and other current assets totaled $0.2 million and $0.3 million as of June 30, 2025 and December 31, 2024, respectively.

7

Table of Contents

4. Fair Value Measurements

The Company has certain financial assets recorded at fair value, which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.

Level 1—Quoted market prices in active markets for identical assets or liabilities.

Level 2—Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.

Level 3—Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use.

To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The following tables set forth the fair value of the Company’s financial assets by level within the fair value hierarchy as of June 30, 2025 and December 31, 2024:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

June 30, 2025

​

​

​

​

​

​

​

​

Significant

​

​

​

​

​

​

​

​

Quoted Prices in

​

Other

​

​

​

​

​

​

​

​

Active Markets or

​

Observable

​

Significant

​

​

​

​

​

Identical Assets

​

Inputs

​

Unobservable

(in thousands)

    

Total

    

(Level 1)

    

(Level 2)

    

(Level 3)

Cash equivalents:

​

​

​

​

​

​

​

​

​

​

​

​

Money market funds

​

$

3,914

​

$

3,914

​

$

—

​

$

—

Marketable securities:

​

​

​

​

​

​

​

​

​

​

​

​

Corporate bonds

​

​

22,938

​

​

—

​

​

22,938

​

​

—

U.S. Treasury and Government agencies

​

​

7,478

​

​

—

​

​

7,478

​

​

—

Total

​

$

34,330

​

$

3,914

​

$

30,416

​

$

—

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

December 31, 2024

​

​

​

​

​

​

​

​

Significant

​

​

​

​

​

​

​

​

Quoted Prices in

​

Other

​

​

​

​

​

​

​

​

Active Markets or

​

Observable

​

Significant

​

​

​

​

​

Identical Assets

​

Inputs

​

Unobservable

(in thousands)

    

Total

    

(Level 1)

    

(Level 2)

    

(Level 3)

Cash equivalents:

​

​

​

​

​

​

​

​

​

​

​

​

Money market funds

​

$

27,057

​

$

27,057

​

$

—

​

$

—

Marketable securities:

​

​

​

​

​

​

​

​

​

​

​

​

Corporate bonds

​

​

32,517

​

​

—

​

​

32,517

​

​

—

U.S. Treasury and Government agencies

​

​

8,377

​

​

—

​

​

8,377

​

​

—

Total

​

$

67,951

​

$

27,057

​

$

40,894

​

$

—

​

​

The Company did not transfer any assets measured at fair value on a recurring basis between levels during the three months ended June 30, 2025.

8

Table of Contents

5. Leases

The Company's lease portfolio consists of office space and laboratory facilities. All of the Company's leases are classified as operating leases. The terms of the Company's lease agreements currently extend through March 2030 and provide the Company with an option for a five-year extension. Under the terms of the leases, the Company pays base annual rent subject to fixed dollar increases each year and other normal operating expenses such as taxes, repairs, and maintenance. The Company evaluates renewal options at lease inception and on an ongoing basis and considers renewal options that the Company is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities in accordance with Accounting Standards Codification (“ASC”) 842. The leases do not require variable lease payments or residual value guarantees and do not contain restrictive covenants.

The leases do not provide an implicit rate; therefore, the Company uses its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease.

Operating lease expense was $252,000 and $254,000 for the three months ended June 30, 2025 and June 30, 2024, respectively. Operating lease expense was $504,000 and $526,000 for the six months ended June 30, 2025 and June 30, 2024, respectively. Operating cash flows used for operating leases during the six months ended June 30, 2025 and June 30, 2024 were $575,000 and $559,000, respectively. As of June 30, 2025, the weighted-average remaining lease term was 4.75 years, and the weighted average discount rate was 7.46%.

As of June 30, 2025, the maturities of the Company’s operating lease liabilities were as follows (in thousands), which are included in Accrued liabilities and other liabilities and Lease liabilities, long term in the accompanying balance sheet: 

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

​

​

 

​

​

2025

​

$

639

​

​

​

2026

​

 

1,355

​

​

​

2027

​

 

1,396

​

​

​

2028

​

 

1,438

​

​

​

2029

​

​

1,481

​

​

​

Thereafter

​

 

376

​

​

​

Total future minimum payments

​

$

6,685

​

​

​

Less: present value discount

​

​

(1,095)

​

​

​

Present value of lease liabilities

​

$

5,590

​

​

​

​

​

​

​

​

​

​

​

6. Stock-Based Compensation

Employee Equity Plans

The NextCure, Inc. 2015 Omnibus Incentive Plan (the “2015 Plan”) was adopted in December 2015 and provides for the grant of awards of stock options, restricted stock awards, unrestricted stock awards and restricted stock units to employees, consultants, and directors of the Company.

The NextCure, Inc. 2019 Omnibus Incentive Plan (the “2019 Plan”) became effective on May 8, 2019, the date on which the Company’s Registration Statement on Form S-1 filed in connection with the Company’s initial public offering was declared effective (the “Effective Date”). The Company’s board of directors (the “Board”) determined not to make additional awards under the 2015 Plan following the effectiveness of the 2019 Plan. The 2019 Plan provides for the grant of awards of stock options, stock appreciation rights, restricted stock, restricted stock units, deferred stock units, unrestricted stock, dividend equivalent rights, other equity-based awards and cash bonus awards to the Company’s officers, employees and non-employee directors as well as other key persons (including consultants).

9

Table of Contents

The number of shares of common stock reserved for issuance under the 2019 Plan is 241,666 plus the number of shares of stock related to awards outstanding under the 2015 Plan that subsequently terminate by expiration or forfeiture, cancellation or otherwise without the issuance of such shares. The number of shares reserved for issuance under the 2019 Plan automatically increase each January 1st during the term of the 2019 Plan by 4% of the number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year or such lesser number of shares determined by the Board.

​

As of June 30, 2025, 81,7467 shares were reserved for future grant under the 2019 Plan.

Stock options granted under the 2015 Plan and 2019 Plan (together, the “Plans”) to employees generally vest over four years and expire after ten years.

A summary of stock option activity for awards under the Plans is presented below:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Options Outstanding and Exercisable

​

​

​

​

​

​

​

Weighted

​

​

​

​

​

​

​

Weighted

​

Average

​

Aggregate

​

​

​

​

Average

​

Remaining

​

Intrinsic

​

​

Number of

​

Exercise

​

Contractual

​

Value(1)

​

    

Shares

    

Price

    

Life (Years)

    

(in thousands)

Outstanding as of December 31, 2024

 

737,895

​

$

83.84

 

7.1

​

$

22

Granted

​

120,198

​

$

9.32

​

—

​

​

—

Exercised

​

—

​

$

—

​

—

​

​

—

Forfeitures

​

(3,006)

​

$

35.59

​

—

​

​

—

Outstanding as of June 30, 2025

​

855,087

​

$

73.53

​

7.0

​

​

—

Exercisable as of June 30, 2025

 

600,038

​

$

98.15

 

6.2

​

$

—

(1)The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money at December 31, 2024 and June 30, 2025.

The weighted average grant date fair value of stock options granted to employees for the six months ended June 30, 2025 was $7.16 using the Black-Scholes option pricing model. No stock options were exercised during the six months ended June 30, 2025. As of June 30, 2025, there was $2.8 million of total unrecognized compensation expense related to unvested options under the Plans that will be recognized over a weighted-average period of approximately 2.2 years.

The aggregate grant date fair value of stock options vested during the six months ended June 30, 2025 and 2024 was approximately $3.7 million and $3.1 million, respectively.

Stock-based compensation expense was classified on the statements of operations as follows for the three months ended June 30, 2025 and 2024:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Six Months Ended

​

​

​

June 30, 

​

June 30, 

​

(in thousands)

    

2025

    

2024

    

2025

    

2024

​

Research and development

​

$

285

​

$

714

​

$

865

​

$

1,383

​

General and administrative

​

 

302

​

 

880

​

 

1,086

​

 

1,904

​

Total stock-based compensation expense

​

$

587

​

$

1,594

​

$

1,951

​

$

3,287

​

​

​

10

Table of Contents

The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:

​

​

​

​

​

​

​

​

​

​

​

Six Months Ended

​

​

​

June 30, 

​

​

    

2025

    

2024

​

Expected term

 

6.0

years 

​

5.8

years 

​

Expected volatility

 

90.5

%

​

83.3

%

​

Risk free interest rate

 

4.4

%

​

4.1

%

​

Expected dividend yield

 

—

%

​

—

%

​

​

​

Employee Stock Purchase Plan

The NextCure, Inc. 2019 Employee Stock Purchase Plan (the “ESPP”) was approved in May 2019 and provides for eligible employees of the Company to purchase shares of Company stock at a discounted price. As of June 30, 2025, 23,767 shares of common stock had been issued pursuant to the ESPP and 88,714 shares were reserved for future issuance thereunder.

7. Mezzanine Equity

On June 13, 2025, the Company entered into a License Agreement (the “Licensing Agreement”) with Hainan Simcere Zaiming Pharmaceutical Co., Ltd. (“Zaiming”), a biopharmaceutical company based in China (see Note 8, License Agreement). In connection with the Licensing Agreement, the Company also entered into a Subscription Agreement (the “Subscription Agreement”) pursuant to which the Company issued and sold to Simcere Zaiming, Inc. (“Simcere Zaiming”), a Delaware corporation and an affiliate of Zaiming, in a private placement (the “Private Placement”), an aggregate of 338,636 shares (the “Shares”) of the common stock of the Company, par value $0.001 per share, at a price of approximately $5.904 per Share for an aggregate purchase price of $2.0 million. Additionally, the Company entered into a Registration Rights Agreement with Simcere Zaiming on June 13, 2025 (the “Registration Rights Agreement”), pursuant to which the Company is obligated (i) to prepare and file with the SEC a registration statement (the “Registration Statement”) to register for resale the Shares, and (ii) to use its reasonable best efforts to cause the Registration Statement to be declared effective by the SEC as soon as practicable, in each case subject to certain deadlines. Should the Company not complete the registration with the SEC within nine months of June 13, 2025, Simcere Zaiming has the right to terminate the Subscription Agreement and shall be entitled to demand that the Company repurchase such Shares at a repurchase price equal to the purchase price that Simcere Zaiming paid for the Shares.

​

Under ASC 480, Distinguishing Liabilities from Equity, contingently redeemable equity securities, including those that are redeemable upon an event outside the control of the Company, are prohibited from being classified as part of stockholders’ equity. Since Simcere Zaiming has the right to demand that the company repurchase the Shares if the Shares are not registered with the SEC, and SEC approval is outside the control of the Company, the issued shares can not be classified as permanent equity and were classified as mezzanine equity as of June 30, 2025. Mezzanine equity is presented after liabilities and before stockholders’ equity on the condensed balance sheet. Once the shares have been registered with the SEC, they will be reclassified as stockholders’ equity.

​

After the balance sheet date, on July 18, 2025, the Company filed a registration statement with the SEC to register the shares. On July 29, 2025, the SEC delared the shares to be effectively registered. Thus, the shares were reclassified from mezzanine equity to permanent equity on that date.

​

8. License Agreement

Pursuant to the Licensing Agreement entered into with Zaiming on June 13, 2025, the Company obtained (1) an exclusive, worldwide (excluding the Zaiming Territory, as identified below) license to develop, manufacture, and commercialize Zaiming’s clinical-stage antibody drug conjugate (“ADC”) candidate, SIM0505 (also known as SCR-9359), and related compounds (the “Zaiming Products”), and (2) a non-exclusive, worldwide (excluding the Zaiming

11

Table of Contents

Territory) license to use Zaiming’s ADC platform technology to develop ADCs based on the Company’s proprietary antibodies for an additional novel target (the “NextCure Products”). Zaiming retained exclusive rights to develop and commercialize the Zaiming Products and any NextCure Products in mainland China, Hong Kong, Macau, and Taiwan (the “Zaiming Territory”).

​

Under the Licensing Agreement: (i) the Company agreed to pay $17 million to Zaiming, which includes an upfront cash payment of $12 million (the “Initial Payment”) and an additional $5 million that becomes payable upon the earlier of a qualifying financing event or December 31, 2025; (ii) upon initiation of the first Phase 2 clinical trial for SIM0505, the Company will issue to Zaiming $1 million in its common stock, or under certain conditions, pay an equivalent cash amount in lieu of common stock; (iii) the Company will pay Zaiming development and regulatory milestone payments of up to $166.5 million per Zaiming Product and up to $25.5 million per NextCure Product, and commercial sales-based milestone payments of up to $535 million; and (iv) the Company will pay tiered royalties on annual net sales of licensed products, at rates ranging from mid-single digit to low double digit percentages for Zaiming Products; and low to mid-single digit percentages for NextCure Products, in all cases, subject to standard reductions.

​

The rights acquired under the Licensing agreement are considered in-process research and development (IPRD) under ASC 730, Research and Development. Specifically, ASC 730-10-25-(c) states intangible assets used in research and development activities acquired in an asset acquisition should be expensed at the acquisition date if there is no alternative future use in other research and development projects. Since the acquired asset is the right to a specific compound, the Company does not believe there is an alternative future use and expensed both the upfront $12 million payment and the additional $5 million payment that is due no later than December 31, 2025. This $17 million is included in research and development costs in the condensed statement of operations. None of the milestone payments are considered probable and reasonably estimated as of June 30, 2025, so they were not accrued.

​

9. Collaboration Agreement

Collaboration Agreement with LigaChem Biosciences, Inc. (“LigaChem”), formerly known as LegoChem Biosciences

In November 2022, the Company entered into a Research Collaboration and Co-Development Agreement (“Agreement”) with LigaChem to develop up to three antibody drug conjugates.  Under the terms of the Agreement, both parties equally share the costs of developing the molecules and profits on commercialized products.  The collaboration consists of up to three research programs for which a research plan will be developed.  With respect to a research plan, each party must use reasonable efforts to execute and perform the activities assigned to it.  Each party is solely responsible for costs associated with its assigned activities as outlined in the research plan.  Upon successful completion of a research plan, or as otherwise agreed, the parties may designate a research product as a co-development product.  Upon designation of a co-development product, cost sharing on a 50-50 basis between the Company and LigaChem would begin.  The activities associated with the research plan and any co-development products are to be coordinated by a joint steering committee, which is comprised of an equal number of representatives from the Company and LigaChem.  If and when a co-development product becomes commercialized, the Company and LigaChem would equally share in the profits.  There are no implied licenses or other rights created under this Agreement after designation of a co-development product.  

Effective April 1, 2023, the parties designated the initial co-development product under the Agreement.  As such, cost sharing on a 50-50 basis commenced for the first co-development product under the Agreement.  

Given the involvement by both parties under this Agreement, management assessed the criteria under ASC 808 to determine if the Agreement is within the scope of ASC 808. Based on the terms of the Agreement, the Company concluded that the Agreement meets the requirements of a collaboration within the guidance of ASC 808.  The Company and LigaChem are active participants in the activities associated with the Agreement and are exposed to significant risks and rewards dependent on the commercial success of the activity encompassed thereby.  The Agreement is not reflective of a vendor-customer relationship and therefore not within the scope of ASC 606.  Accordingly, the net costs associated with the co-development pursuant to the Agreement are expensed as incurred and recognized within research and development expenses on the statement of operations.

12

Table of Contents

As of June 30, 2025, LNCB74 was the only co-development product and was in the early stages of development.  During the three months ended June 30, 2025, the Company incurred more costs than LigaChem under the Agreement, and was entitled to $1.0 million in reimbursement from LigaChem, reflecting the 50-50 cost sharing terms under the Agreement.  As of June 30, 2025, the Company recorded a receivable from LigaChem of $1.0 million.

10. Restructuring and Asset Impairment

On March 19, 2024, the Board approved a restructuring plan and prioritization (the “2024 Restructuring”) of its clinical portfolio to focus on what the Board believed to be the Company’s highest-value opportunities in NC410 (ovarian and colorectal cancer) and LNCB74 (B7-H4 ADC).  In addition to prioritizing these programs, the Company paused its internal manufacturing operations and reduced its workforce by approximately 37%.

Employees affected by the reduction in force under the 2024 Restructuring were entitled to receive severance payments and Company-funded medical insurance for a specified time. During the three months ended June 30, 2024, the Company recognized $0.8 million for employees who had no requirements for future service upon approval of the 2024 Restructuring.  This $0.8 million was paid out in full during the three months ended June 30, 2024, and there is no remaining liability as of June 30, 2025.

The Company also completed an evaluation of the impact of the 2024 Restructuring on the carrying value of its long-lived assets.  Our evaluation determined that indicators of impairment were present within right of use assets and property and equipment. Where impairment indicators existed, the Company evaluated the identified asset group and separately compared the estimated undiscounted cash flow for each asset group to the net book value of the related long-term asset. Based on this evaluation, the Company determined an impairment was present and then calculated the amount of the impairment by developing a fair value estimate of the asset group that was compared to the carrying value. 

The Company recorded $1.8 million of impairment charges related to a facility operating lease asset and accelerated depreciation on manufacturing equipment for the three months ended June 30, 2024. No additional impairment charges were recorded through June 30, 2025. 

Assumptions used in this analysis included current real estate trends, length of time to enter into a sublease and the discount rate used to develop the present value estimate.   Other assumptions included an estimate of the salvage value for manufacturing equipment that is no longer in use.  These assumptions are considered nonrecurring Level 3 estimates.

11. Segment Information

We operate our business in one operating segment, which also represents one reportable segment: life sciences. The life sciences segment focuses on advancing innovative medicines that, in the case of the Company, treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of differentiated mechanisms of action including ADCs. The Company’s chief operating decision maker (“CODM”) is the chief executive officer.

The accounting policies of the life sciences segment are the same as those described in Note 2, Summary of Significant Accounting Policies. The CODM assesses performance for the life science segment based on net loss, which is reported on the statements of operations and comprehensive net loss as net loss. The measure of segment assets is reported on the balance sheet as total assets.

To date, the Company has not generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances product candidates through all stages of development and clinical trials and, ultimately, seek regulatory approval.

As such, the CODM uses cash forecast models in deciding how to invest into the life sciences segment. Such cash forecast models are reviewed to assess the entity-wide operating results and performance. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus actual results is used in assessing performance of the segment and in establishing management’s compensation, along with cash forecast models.

13

Table of Contents

The tables below summarize the significant expense categories regularly reviewed by the CODM for the three and six months ended June 30, 2025 and 2024:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Six Months Ended

(in thousands)

​

June 30, 

​

June 30, 

​

​

2025

    

2024

    

2025

    

​

2024

Research and development expenses

​

​

​

​

​

​

​

​

​

​

​

​

Employee costs

​

$

2,341

​

$

3,507

​

$

5,271

​

$

7,757

Clinical product candidates

​

​

2,569

​

​

4,563

​

​

5,604

​

​

9,523

Nonclinical product candidates

​

​

981

​

​

2,981

​

​

1,646

​

​

3,793

Depreciation and amortization

​

​

618

​

​

682

​

​

1,254

​

​

1,453

Other R&D (1)

​

​

17,582

​

​

685

​

​

18,212

​

​

1,290

Total R&D

​

$

24,091

​

$

12,418

​

$

31,987

​

$

23,816

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

General and administrative expenses

​

​

​

​

​

​

​

​

​

​

​

​

Employee costs

​

$

1,374

​

$

2,144

​

$

3,451

​

$

4,595

Professional services

​

​

1,266

​

​

1,096

​

​

2,346

​

​

2,245

Insurance

​

​

243

​

​

334

​

​

505

​

​

758

Other G&A (2)

​

​

318

​

​

502

​

​

625

​

​

842

Total G&A

​

$

3,201

​

$

4,076

​

$

6,927

​

$

8,440

​

(1)Other R&D consists of facilities related expenses and office expenses and includes $17 million related to the license agreement entered into in June 2025 for both the three and six months ended June 30, 2025 (Note 8).
(2)Other G&A consists of facilities related expenses, depreciation, office expenses and taxes and fees.

​

12. Net Loss Per Share Attributable to Common Stockholders

The computation of basic loss per share is based on the weighted-average number of common shares outstanding, without consideration for dilutive common stock equivalents. The computation of diluted loss per share is based on the weighted-average number of common shares outstanding and dilutive potential common shares, which include shares that may be issued under the 2015 Plan and 2019 Plan, as determined using the treasury stock method.

The computation for basic and diluted loss per share were as follows (in thousands, except share and per share data):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Six Months Ended

​

​

​

June 30, 

​

June 30, 

​

​

    

2025

    

2024

    

2025

    

2024

​

Net loss (Numerator):

 

​

  

​

​

  

 

​

  

​

​

  

 

Net loss - basic and diluted

​

$

(26,808)

​

$

(15,404)

​

$

(37,784)

​

$

(32,511)

​

Shares (Denominator):

​

 

  

​

 

  

​

 

  

​

 

  

​

Weighted-average shares outstanding - basic and diluted

​

 

2,374,729

​

 

2,331,062

​

 

2,354,425

​

 

2,328,157

​

Loss per share - basic and diluted

​

$

(11.29)

​

$

(6.61)

​

$

(16.05)

​

$

(13.96)

​

​

​

For the three months ended June 30, 2025 and 2024, all options to purchase shares of the Company’s common stock were excluded from the computation of diluted net loss per share as the effect would have been anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.

14

Table of Contents

The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:

​

​

​

​

​

​

​

​

​

June 30, 

​

    

2025

    

2024

Outstanding options to purchase common stock

 

​

855,087

​

759,046

Total

 

​

855,087

​

759,046

​

​

13. Income Taxes

The Company did not record a provision or benefit for income taxes during the three month periods ended June 30, 2025 and 2024. The Company continues to maintain a full valuation allowance against its deferred tax assets.

The Company has evaluated the positive and negative evidence involving its ability to realize its deferred tax assets. Management has considered the Company’s history of cumulative net losses incurred since inception and its lack of any commercially ready products. It has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Management reevaluates the positive and negative evidence at each reporting period.

Under the provisions of Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the “IRC”), certain substantial changes in the Company’s ownership may have limited, or may limit in the future, the amount of net operating loss and research and development credit carryforwards that can be used to reduce future income taxes. We have not performed a detailed analysis to determine whether an ownership change under Section 382 of the IRC occurred. The effect of an ownership change would be the imposition of an annual limitation on the use of losses and credits attributable to periods before the change and could result in a reduction in the total losses and credits available.

14. Commitments and Contingencies

Legal Proceedings

From time to time, the Company is a party to litigation or legal proceedings arising in the ordinary course of business. The Company is not currently a party to any litigation or legal proceeding, nor is management aware of any pending or threatened litigation that, in the opinion of the Company’s management, is likely to materially affect the Company’s business or financial results. At each reporting date, the Company evaluates whether a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses the costs related to its legal proceedings as incurred.

15. Subsequent Events

​

On January 31, 2025, the Company received written notice (the “Notice”) from the Listing Qualifications Department of Nasdaq notifying us that the closing price of our common stock over the prior 30 consecutive business days had fallen below $1.00 per share, which is the minimum average closing price required to maintain listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we had 180 calendar days, or until July 30, 2025, to regain compliance with the Minimum Bid Requirement, subject to a potential 180 calendar day extension (the “Grace Period”). To regain compliance, the closing bid price of our common stock must have been at least $1.00 per share for a minimum of ten consecutive business days within the Grace Period.

​

As discussed above in Note 1, Nature of the Business, on July 10, 2025, the Company filed an amendment (the “Reverse Split Amendment”) to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a one-for-twelve (1:12) reverse stock split of the Company's shares of common stock. As a result of the Reverse Stock Split, every 12 shares of common stock outstanding immediately prior to effectiveness of the Reverse Stock Split were combined and converted into one share of common stock without any change in the par value per share. The Reverse Stock Split became effective on July 14, 2025, and the common stock was quoted on the Nasdaq

15

Table of Contents

Stock Market on a post-split basis at the open of business on July 14, 2025. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who would have otherwise been entitled to a fraction of one share of common stock as a result of the Reverse Stock Split instead received a proportional cash payment. The reverse stock split affected all shares of the Company’s common stock outstanding immediately prior to the effective date of the reverse stock split, as well as the number of shares of common stock available for issuance under the Company’s equity incentive plan. In addition, the reverse stock split effected a reduction in the number of shares of common stock issuable upon the exercise of stock options.  On July 28, 2025, the Company received a letter from Nasdaq informing us that our common stock had regained compliance with the Minimum Bid Requirement.

​

 All share and per share data for all periods presented in the accompanying financial statements and the related disclosures in this Quarterly Report on Form 10-Q have been adjusted retrospectively to reflect the Reverse Stock Split.

​

On July 18, 2025, the Company filed a registration statement with the SEC to register the shares issued pursuant to the Subscription Agreement (See Note 7, Mezzanine Equity).  On July 29, 2025, the SEC delared the shares to be effectively registered.  Thus, the shares were reclassified from mezzanine equity to permanent equity on that date.

​

​

​

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited condensed financial statements and the notes thereto included in this Quarterly Report and the audited financial information and related notes, as well as Management’s Discussion and Analysis of Financial Condition and Results of Operations and other disclosures, included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, or our “2024 Annual Report.” Some of the statements contained in this discussion and analysis or set forth elsewhere in this Quarterly Report are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “continue,” “could,” “due,” “estimate,” “expect,” “intend,” “may,” “objective,” “plan,” “predict,” “project,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or similar language. Forward-looking statements include, but are not limited to, statements about:

●our expectations regarding the timing, progress and results of preclinical studies and clinical trials for LNCB74, SIM0505 and any other product candidates we develop, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;
●our estimates regarding our expenses, future revenues, capital requirements, needs for or ability to obtain additional financing and the period over which we expect our current cash, cash equivalents and marketable securities to be sufficient to fund our operations;
●the timing or likelihood of regulatory filings for LCNB74, SIM0505 and any other product candidates we develop and our ability to obtain and maintain regulatory approvals for such product candidates for any indication;
●the identification, analysis and use of biomarkers and biomarker data;
●our drug product sourcing and manufacturing strategy, including the scalability of our methods and processes;
●our expectations regarding the potential benefits, activity, effectiveness and safety of LNCB74, SIM0505 and any other product candidates we develop;
●our intentions and ability to successfully commercialize, including through partnering, our product candidates;
●our expectations regarding the nature of the biological pathways we are targeting;
●our expectations regarding our ability to discover and advance product candidates using our technologies;
●the potential benefits of and our ability to maintain our relationship with LigaChem Biosciences, Inc., (formerly known as LegoChem Bioscienses, Inc. or hereinafter “LigaChem”), Hainan Simcere Zaiming Pharmaceutical, Ltd., Yale University (“Yale”), and other third parties;
●our ability to retain key personnel;

16

Table of Contents

●our intended reliance on and the performance of third parties, including collaborators, contract research organizations and third-party manufacturers;
●changes in trade tariffs and international relations between the U.S. and China;
●our ability to protect and enforce our intellectual property protection and the scope and duration of such protection;
●our ability to maintain listing of our common stock on the Nasdaq Global Select Market;
●developments and projections relating to our competitors and our industry, including competing therapies; and
●the impact of current and future laws and regulations.

Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: the potential that positive results in preclinical studies may not be predictive of the results of clinical trials; our limited operating history and lack of any products approved for commercial sale; our history of significant losses; our need and ability to obtain additional financing on acceptable terms or at all; risks related to clinical development, marketing approval and commercialization; the unproven approach to the discovery and development of product candidates based on our technologies; risks related to our restructuring and reduction in force; and our dependence on key personnel. More detailed information on these and additional factors that could affect our actual results are described under the heading “Risk Factors” in our 2024 Annual Report and in our other filings with the Securities and Exchange Commission (the “SEC”). You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this report, and we assume no obligation to update any forward-looking statements, even if expectations change.

We are a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies, including antibody-drug conjugates (“ADCs”), antibodies and proteins. An ADC consists of a monoclonal antibody conjugated to a cytotoxic drug via a chemical linker. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response.

Our product candidate LNCB74 is designed as a state-of-the-art B7-H4 targeted ADC to kill tumors.  B7-H4, a clinically validated target, is a cell surface protein expressed on multiple tumor types including breast, ovarian, and endometrial cancers. LNCB74 will be positioned with both potential improved safety and efficacy compared to other ADCs targeting B7-H4.  Preclinical studies demonstrated potent tumor killing in disease models and a favorable safety profile.  LNCB74 is being advanced under a November 2022 Research Collaboration and Co-Development Agreement with LigaChem.  

In December 2024, we announced that the U.S. Food and Drug Administration (the “FDA”) accepted an Investigational New Drug (“IND”) application for initiation of a Phase 1 clinical trial to evaluate LNCB74 for treating multiple cancers known to have high B7-H4 expression, including breast, ovarian, and endometrial cancers.  Since announcing in January 2025 that the first patient in our Phase 1 trial of LNCB74 had been dosed, we cleared cohort 3 in June 2025 and are currently within cohort 4 of the dose escalation portion of the Phase 1 trial.  We plan to initiate backfill cohorts in the second half of 2025, provide a program update by the fourth quarter of 2025, and provide proof of concept data readout in the first half of 2026.

We announced in June 2025 a license agreement and began a strategic partnership to develop SIM0505, a novel ADC candidate developed by Zaiming.  It is directed to CDH6 (cadherin-6 or K-cadherin), a promising anti-tumor target, using a unique binding epitope designed to have increased tumor binding compared to competing candidates. It also features Zaiming’s proprietary topoisomerase 1 inhibitor (TOPOi) payload, designed for broad anti-tumor activity while offering high systemic clearance to enlarge the therapeutic window. Preclinical studies have demonstrated robust anti-tumor activity across multiple solid tumor models and a promising safety profile in toxicology models.

Zaiming is currently in Phase 1 dose escalation studies in China with SIM0505 for the treatment of solid tumors, including ovarian, endometrial, and renal. In December 2024, Zaiming received clearance from the FDA for its IND for a Phase 1 clinical trial for treating multiple cancers.  We received notification by the FDA in June 2025 of the assignment

17

Table of Contents

of the IND to NextCure.  We anticipate dosing our first patient in the third quarter of 2025, provide a program update by the fourth quarter of 2025, and expect to provide proof of concept data readout in the first half of 2026.

In addition, we are seeking to partner our other clinical programs NC410 and NC525 and to pursue a partner or third-party financing to advance our preclinical non-oncology programs NC605 and NC181.

In March 2024, we announced a prioritization and restructuring of our operations to align with our focused pipeline (the “2024 Restructuring”). We paused our internal manufacturing operations and reduced our workforce. In part because of these actions, we expect to be able to fund our operations into mid-2026 with our existing cash position of approximately $35.3 million as of June 30, 2025.

Financial Overview

Since commencing operations in 2015, we have devoted substantially all of our efforts and financial resources to organizing and staffing our company, identifying business development opportunities, raising capital, securing intellectual property rights related to our product candidates, building and optimizing our manufacturing capabilities and conducting discovery, research and development activities for our product candidates.

To date, we have not generated any revenue from product sales and have financed our operations primarily through proceeds from public offerings of our common stock, with private placements of our preferred stock and with upfront fees received under our former research and development collaboration agreement. Since inception through June 30, 2025, we raised approximately $423 million in gross proceeds from the sale of equity instruments and had received a $25 million upfront payment from our former collaboration partner. We have never been profitable and have incurred net losses since the commencement of our operations. Our net loss for the three months ended June 30, 2025 and 2024, was $26.8 million and $15.4 million, respectively.  Our net loss for the six months ended June 30, 2025 and 2024, was $37.8 million and $32.5 million, respectively.  As of June 30, 2025, we had an accumulated deficit of $417.9 million, primarily as a result of research and development and general and administrative expenses. We do not expect to generate product revenue unless and until we obtain marketing approval for and commercialize a product candidate, and we cannot make assurances that we will ever generate significant revenue or profits.

As of June 30, 2025, we had cash, cash equivalents and marketable securities of $35.3 million. We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our planned operations into mid-2026.  However, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the issuance of the condensed financial statements.

We expect to incur substantial expenditures in the foreseeable future as we advance LNCB74 through clinical development, the regulatory approval process and, if approved, commercialization. Specifically, in the near term, we expect to incur expenses relating to clinical development activities with respect to LNCB74, SIM0505 and other research and development activities.

We will need substantial additional funding to support our continuing operations and to pursue our development strategy. Until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our operations through a combination of public and private equity offerings, debt financings, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements. Adequate funding may not be available to us on acceptable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may be required to delay, limit, reduce or terminate preclinical studies, clinical trials, or other research and development activities or one or more of our development programs.

18

Table of Contents

Components of Our Results of Operations

Operating Expenses

Research and Development Expenses

Research and development expenses consist primarily of costs incurred for our clinical trials, discovery efforts, research activities, and development and testing of our product candidates and include:

●the costs of acquired in-process research and development;
●expenses incurred under agreements with third parties, including agreements with third parties that conduct research, preclinical activities or clinical trials on our behalf;
●the costs of outside consultants, including their fees, stock-based compensation and related travel expenses;
●the costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials;
●salaries, benefits and other related costs, including stock-based compensation, for personnel engaged in research and development functions; and
●facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.

We expense research and development costs as incurred. Our expenses related to clinical trials are based on actual costs incurred and estimates of other incurred costs. These estimated costs are based on several factors, including patient enrollment and related expenses at clinical investigator sites, contract services received, consulting agreement costs and efforts expended under contracts with research institutions and third-party contract research organizations that conduct and manage clinical trials on our behalf. We generally accrue estimated costs related to clinical trials based on contracted amounts applied to the level of patient enrollment and other activity according to the protocol. If future timelines or contracts are modified based on changes in the clinical trial protocol or scope of work to be performed, we would modify our estimates of accrued expenses accordingly on a prospective basis. Historically, any such modifications have not been material.

Research and development activities are central to our business model. We expect that our research and development expenses will increase substantially in the future as we advance our product candidates through development.

We cannot determine with certainty the duration and costs of future clinical trials of  LNCB74, SIM0505 or any other product candidate we may develop or if, when or to what extent we will generate revenue from the commercialization and sale of any product candidate for which we may obtain marketing approval. We may never succeed in obtaining marketing approval for any product candidate. The duration, costs and timing of clinical trials and development of LNCB74, SIM0505 and any other product candidate we may develop will depend on a variety of factors, including:

●the scope, progress, results and costs of clinical trials of LNCB74, SIM0505 as well as of any future clinical trials of other product candidates and other research and development activities that we may conduct;
●our ability to obtain partnerships for our other programs;
●uncertainties in selection of indications, clinical trial design and patient enrollment rates;
●the probability of success for our product candidates, including safety and efficacy, early clinical data, competition, ease and ability of manufacturing and commercial viability;

19

Table of Contents

●significant and changing government regulation and regulatory guidance;
●the timing and receipt of any development or marketing approvals; and
●the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.

A change in the outcome of any of these variables with respect to the development of a product candidate could lead to a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time to complete clinical development for any such product candidate.

General and Administrative Expenses

General and administrative expenses consist primarily of personnel-related costs, including payroll and stock-based compensation, for personnel in executive, finance, human resources, business and corporate development and other administrative functions, professional fees for legal, intellectual property, consulting and accounting services, rent and other facility-related costs, depreciation and other general operating expenses not otherwise classified as research and development expenses. General and administrative expenses also include all patent-related costs incurred in connection with filing and prosecuting patent applications, which are expensed as incurred.

Restructuring and Asset Impairment Charges

Restructuring and asset impairment charges consist of severance charges associated with a reduction in force, and include salary continuation, payroll taxes and company funded benefits.  Asset impairment charges reflect the write-down of long-lived assets that are considered impaired under ASC 360.

Other Income, Net

Other income, net consists primarily of interest income earned on marketable securities.

Results of Operations

Comparison of the Three and Six Months Ended June 30, 2025 and 2024

The following table summarizes our results of operations for the periods indicated (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

    

​

​

​

Six Months Ended

​

​

​

​

​

​

June 30, 

​

​

​

​

June 30, 

​

​

​

​

​

    

2025

    

2024

    

Change

    

2025

    

2024

    

Change

​

Operating expenses:

 

​

  

 

​

  

 

​

  

 

​

  

 

​

  

 

​

  

 

Research and development

​

$

24,091

​

$

12,418

​

$

11,673

​

$

31,987

​

$

23,816

​

$

8,171

​

General and administrative

​

 

3,201

​

 

4,076

​

 

(875)

​

 

6,927

​

 

8,440

​

 

(1,513)

​

Restructuring and asset impairment charges

​

​

—

​

​

—

​

​

—

​

​

—

​

​

2,542

​

​

(2,542)

​

Loss from operations

​

 

(27,292)

​

 

(16,494)

​

 

(10,798)

​

 

(38,914)

​

 

(34,798)

​

 

4,116

​

Other income, net

​

 

484

​

 

1,090

​

 

(606)

​

 

1,130

​

 

2,287

​

 

(1,157)

​

Net loss

​

$

(26,808)

​

$

(15,404)

​

$

(11,404)

​

$

(37,784)

​

$

(32,511)

​

$

5,273

​

20

Table of Contents

​

Research and Development Expenses

The following table summarizes our research and development expenses by product candidate for the periods indicated (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

​

​

​

Six Months Ended

​

​

​

​

​

June 30, 

​

​

​

​

June 30, 

​

​

​

(in thousands)

    

2025

    

2024

    

Change

    

2025

    

2024

    

Change

External research and development expenses:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

LNCB74, net of cost sharing

​

​

1,363

​

​

2,048

​

​

(685)

​

​

2,016

​

​

2,937

​

​

(921)

SIM0505

​

​

17,000

​

​

—

​

​

17,000

​

​

17,000

​

​

—

​

​

17,000

Other programs and preclinical development

​

​

2,179

​

​

5,496

​

​

(3,317)

​

​

5,396

​

​

12,445

​

​

(7,049)

Total external research and development expenses

​

​

20,542

​

​

7,544

​

​

12,998

​

​

24,412

​

​

15,382

​

​

9,030

Total internal research and development expenses

​

​

3,549

​

​

4,874

​

​

(1,325)

​

​

7,575

​

​

8,434

​

​

(859)

Total research and development expenses

 

$

24,091

​

$

12,418

​

$

11,673

​

$

31,987

​

$

23,816

​

$

8,171

​

We do not allocate personnel-related costs, including stock-based compensation costs, or other indirect costs to specific programs, as they are deployed across multiple projects under development and discovery and, as such, are separately classified as internal research and development expenses in the table above.

Research and development expenses for the three months ended June 30, 2025 increased by $11.7 million compared to the three months ended June 30, 2024 due to $17.0 million of fees associated with the Licensing Agreement dated June 13, 2025 with Zaiming.  These higher costs were partially offset by lower costs on other programs.  Internal costs decreased largely due to lower personnel-related costs, primarily stock compensation costs.

Research and development expenses for the six months ended June 30, 2025 increased by $8.2 million compared to the six months ended June 30, 2024 due to $17.0 million of fees associated with the Licensing Agreement signed in June 2025.  These higher costs were largely offset by lower costs on other programs, largely costs for NC410 and NC525 as the Company previously deprioritized these programs and focused on finding a partner to further develop these programs.  Internal costs also decreased, largely due to lower personnel-related costs.

General and Administrative Expenses

General and administrative expenses for the three months ended June 30, 2025 decreased by $0.9 million compared to the three months ended June 30, 2024. The decrease was driven primarily by $0.8 million lower personnel-related costs, primarily stock compensation costs.

General and administrative expenses for the six months ended June 30, 2025 decreased by $1.5 million compared to the six months ended June 30, 2024. The decrease was driven primarily by $1.1 million lower personnel-related costs, primarily stock compensation costs and lower insurance costs.

Restructuring and Asset Impairment Charges

There were no restructuring and asset impairment charges for the three and six months ended June 30, 2025.  Restructuring and asset impairment charges were $0 and $2.5 million for the three and six months ended June 30, 2024, consisting of $0.7 million of severance charges as a result of a reduction in force and $1.8 million of asset impairment charges associated with the write-down of certain manufacturing equipment, right of use assets and related improvements, each in connection with the 2024 Restructuring.

​

Other Income, Net

Other income, net for the three months ended June 30, 2025 decreased by $0.6 million compared to the three months ended June 30, 2024, due to lower interest income as a result of lower investable cash.

21

Table of Contents

Other income, net for the six months ended June 30, 2025 decreased by $1.2 million compared to the six months ended June 30, 2024, due to lower interest income as a result of lower investable cash.

​

Liquidity and Capital Resources

Since inception through June 30, 2025, we have raised approximately $423 million in gross proceeds from the sale of equity instruments and had received a $25 million upfront payment from our former collaboration partner.

On August 4, 2023, the Company entered into a sales agreement (the “Sales Agreement”) with Leerink Partners LLC (the “Agent”), pursuant to which the Company may sell, from time to time, up to an aggregate sales price of $75 million of its common stock through the Agent in negotiated transactions that are deemed to be an “at the market offering.” The Agent will be entitled to compensation equal to 3.0% of the gross proceeds from the sale of all shares of common stock sold through it as the Agent under the Sales Agreement. Actual sales will depend on a variety of factors to be determined by the Company from time to time, including, among other things, market conditions, the trading price of the common stock, capital needs and determinations by the Company of the appropriate sources of funding for the Company. No shares of common stock were sold in the three months ended June 30, 2025.

As of June 30, 2025, we had cash, cash equivalents and marketable securities of $35.3 million. We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our planned operations into mid-2026.  However, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the issuance of the condensed financial statements.  

See Note 2, Summary of Significant Accounting Policies, to our condensed financial statements included elsewhere in this Quarterly Report on Form 10-Q for additional information on our assessment.  We will continue to require additional capital to develop our product candidates and fund operations for the foreseeable future. We may seek to raise capital through sale of equity, debt financings, strategic alliances and licensing arrangements. Adequate additional funding may not be available to us on acceptable terms or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development of our product candidates. Our need to raise additional capital will depend on many factors, including:

●the scope, progress, results and costs of researching and developing LNCB74, SIM0505 and our other programs, and of conducting preclinical studies and clinical trials;
●the timing of, and the costs involved in, obtaining marketing approvals for LNCB74, SIM0505 and any future product candidates we develop, if clinical trials are successful;
●the costs of manufacturing LNCB74, SIM0505 and any future product candidates we develop for preclinical studies and clinical trials in preparation for marketing approval and commercialization;
●the costs of commercialization activities, including marketing, sales and distribution costs, for LNCB74, SIM0505 and any future product candidates we develop, whether alone or with a collaborator, if any such product candidates are approved for sale, including marketing, sales and distribution costs;
●our ability to establish and maintain additional collaborations, licenses or other arrangements on favorable terms, if at all;
●the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of any such litigation;
●our current collaboration and license agreements remaining in effect and our achievement of milestones and the timing and amount of milestone payments we are required to make, or that we may be eligible to receive, under those agreements;
●the timing, receipt and amount of sales of, or royalties on, our future products, if any; and
●the emergence of competing therapies and other developments in the oncology market.

22

Table of Contents

Adequate additional financing may not be available to us on acceptable terms, or at all. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. If we raise additional funds through government or private grants, collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our future revenue streams, product candidates or research programs or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, reduce or terminate some or all of our development programs and clinical trials. We may also be required to sell or license to others rights to our product candidates in certain territories or indications that we would prefer to retain for ourselves. See the section entitled “Risk Factors” for additional risks associated with our substantial capital requirements.

23

Table of Contents

Cash Flows

The following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods presented below (in thousands):

​

​

​

​

​

​

​

​

​

Six Months Ended

​

​

June 30, 

​

    

2025

    

2024

Net cash (used in) provided by:

 

​

  

 

​

  

Operating activities

​

$

(35,707)

​

$

(22,382)

Investing activities

​

 

10,853

​

 

30,041

Financing activities

​

 

2,019

​

 

107

Net increase (decrease) in cash and cash equivalents

​

$

(22,835)

​

$

7,766

​

Net Cash Used in Operating Activities

Net cash used in operating activities was $35.7 million for the six months ended June 30, 2025, which was primarily the result of our net loss of $37.8 million, and $1.1 million used by net changes in operating assets and liabilities. partially offset by non-cash charges for depreciation of $1.3 million and stock-based compensation of $2.0 million.  Net cash used in operating activities was $22.4 million for the six months ended June 30, 2024, which was primarily the result of our net loss of $32.5 million, partially offset by non-cash charges for depreciation of $1.5 million, stock-based compensation of $3.3 million and impairment charges of $1.8 million, and $3.9 million provided by net changes in operating assets and liabilities.

Net Cash Provided by Investing Activities

Net cash provided by investing activities for the six months ended June 30, 2025 was $10.9 million, which was entirely due to net proceeds from sales and maturities of marketable securities. Net cash provided by investing activities for the six months ended June 30, 2024 was $30.0 million, which was primarily due to net proceeds from sales and maturities of marketable securities of $30.4 million.

Net Cash Provided by Financing Activities

Net cash  provided by financing activities was $2.0 million for the six  months ended June 30, 2025 representing sales of stock issued in connection with the Subscription Agreement, dated as of June 13, 2025, between the Company and Hainan Simcere Zaiming Pharmaceutical Co., Ltd. (see Note 7, Mezzanine Equity). Net cash provided by financing activities was $0.1 million for the six months ended June 30, 2024 representing the exercise of stock options, sales of stock under the ESPP and the sale of 17,151 shares of common stock under the Sales Agreement.

Contractual Obligations and Commitments

Operating Leases

We are party to several non-cancelable lease agreements for office and laboratory space that expire in March 2030. The monthly base rent for these leases totals $97,002 as of June 30, 2025 per month plus our prorated share of operating expenses. The monthly base rent is subject to annual 3% increases through the lease term.

We also have potential contingent payment obligations upon the achievement by us of clinical, regulatory, and commercial events, as applicable, or royalty payments that we may be required to make under license agreements we have entered into with various entities pursuant to which we have in-licensed intellectual property, including our license agreement with Yale. The timing and amount (if any) of any such payments cannot be reasonably estimated at this time.

We enter into contracts in the normal course of business with third-party contract organizations for clinical trials, non-clinical studies and testing, manufacturing and other services and products for operating purposes. These contracts

24

Table of Contents

generally provide for termination following a certain period after notice, and therefore we believe that our non-cancelable obligations under these agreements are not material.There have been no material changes to our contractual obligations during the three months ended June 30, 2025, as compared to those disclosed in our 2024 Annual Report.

Critical Accounting Policies, Significant Judgments and Use of Estimates

Our condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or “GAAP”. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. The most significant assumptions used in the financial statements are the underlying assumptions used in valuing share-based compensation, including the fair value of our common stock in periods before our initial public offering. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions.

During the six months ended June 30, 2025, there were no material changes to our critical accounting policies as reported in our 2024 Annual Report.

Off-Balance Sheet Arrangements

Since our inception, we have not engaged in any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

Recent Accounting Pronouncements

See Note 2, Summary of Significant Accounting Policies, to our unaudited condensed financial statements included elsewhere in this Quarterly Report for a discussion of recent accounting pronouncements that may impact our financial position and results of operations.

​

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a “smaller reporting company” as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), we are not required to provide the information requested by this Item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of June 30, 2025. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of June 30, 2025, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, that occurred during the quarter ended June 30, 2025, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

25

Table of Contents

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

The information set forth under the heading “Legal Proceedings” in Note 14, Commitments and Contingencies, in Notes to Condensed Financial Statements in Item 1 of Part I of this Quarterly Report, is incorporated herein by reference. In addition, from time to time, we are involved in litigation or other legal proceedings as part of our ordinary course of business. In the opinion of our management, the ultimate disposition of these legal proceedings in the ordinary course of business is not likely to have a material adverse effect on our business.

​

Item 1A. Risk Factors.

There have been no material updates to the risk factors set forth in our 2024 Annual Report other than as set forth below:

There is substantial doubt as to our ability to continue as a going concern, which may affect our ability to obtain future financing and may require us to curtail or cease our operations.

The Company has incurred net losses and negative cash flows from operations since its inception, has an accumulated deficit of $417.9 million as of June 30, 2025 and anticipates continuing to incur net losses for the foreseeable future. Under the Company's current plan, management believes its cash and cash equivalents and marketable securities of $35.3 million as of June 30, 2025 will be sufficient to fund the Company's operations into mid-2026. However, the Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the issuance of the condensed financial statements.

As a result, the Company will be required to raise additional capital by partnering, selling equity, or other means. There can be no assurance as to whether partnering efforts will be successful or whether additional financing will be available on terms acceptable to the Company, if at all. If sufficient funds on acceptable terms are not available when needed, it would have a negative impact on the Company’s financial condition and could force the Company to delay, limit, reduce, or terminate product development or future commercialization efforts or grant rights to develop and market product candidates that the Company would otherwise plan to develop and market itself.

If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our audited financial statements, and it is likely that investors will lose all or part of their investment. If we seek additional financing to fund our business activities as a result of the substantial doubt as to our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms or at all.

​

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

There were no sales of equity securities sold during the period covered by this Quarterly Report that were not registered under the Securities Act of 1933 and were not previously reported in a Current Report on Fom 8-K filed by the Company.

​

Item 3. Defaults Upon Senior Securities.

None.

​

26

Table of Contents

Item 4. Mine Safety Disclosures.

Not applicable.

​

Item 5. Other Information.

During the fiscal quarter ended June 30, 2025, none of the Company’s directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1 or any non-Rule 10b5-1 trading arrangement.

​

​

​

27

Table of Contents

Item 6. Exhibits.

The exhibits filed or furnished as part of this Quarterly Report are set forth on the Exhibit Index, below.

​

Exhibit No.

    

Exhibit Description

​

​

​

3.1

​

Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 filed with the Company’s Current Report on Form 8-K filed on July 14, 2025).

​

​

​

10.1*+

​

License Agreement dated June 13, 2025 between the Company and Hainan Simcere Zaiming Pharmaceutical Co., Ltd.

​

​

​

10.2

​

Subscription Agreement, dated as of June 13, 2025, by and between the Company and  Simcere Zaiming, Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 16, 2025).

​

10.3

​

Registration Rights Agreement, dated as of June 13, 2025, by and between the Company and  Simcere Zaiming, Inc. (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on June 16, 2025).

​

​

​

31.1*

​

Certification of Michael Richman pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

​

​

​

31.2*

​

Certification of Steven P. Cobourn pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

​

​

​

32.1**

​

Certification of Michael Richman and Steven P. Cobourn pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

​

​

​

EX-101.INS

​

Inline XBRL Instance Document

​

​

​

EX-101.SCH

​

Inline XBRL Taxonomy Extension Schema Document

​

​

​

EX-101.CAL

​

Inline XBRL Taxonomy Extension Calculation Linkbase Document

​

​

​

EX-101.DEF

​

Inline XBRL Taxonomy Extension Definition Linkbase Document

​

​

​

EX-101.LAB

​

Inline XBRL Taxonomy Extension Label Linkbase Document

​

​

​

EX-101.PRE

​

Inline XBRL Taxonomy Extension Presentation Linkbase Document

​

​

​

104

​

Coverage Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

​

*Filed herewith.

** Furnished herewith.

+Portions of this exhibit have been omitted in compliance with item 601 of Regulation S-K.

​

28

Table of Contents

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​

NEXTCURE, INC.

​

Date: August 7, 2025

By:

/s/ Michael Richman

​

Name:

Michael Richman

​

President and Chief Executive Officer

​

​

​

Date: August 7, 2025

By:

/s/ Steven P. Cobourn

​

Name:

Steven P. Cobourn

​

Chief Financial Officer

​

​

​

​

29

Source:

FAQ

How much cash does NextCure (NXTC) have after Q2 2025?

As of 30-Jun-25, NextCure reported $4.9 m in cash equivalents and $30.4 m in marketable securities, totaling $35.3 m.

What is the company鈥檚 cash runway and going-concern status?

Management believes existing funds support operations into mid-2026, yet disclosed substantial doubt about continuing as a going concern without new capital.

Why did operating expenses jump in Q2 2025?

R&D rose due to a $17 m upfront expense for licensing SIM0505, plus higher spend on Phase 1 trial of LNCB74.

What happened with the reverse stock split?

A 1-for-12 reverse split became effective 14-Jul-25, reducing shares outstanding to about 2.68 m and restoring Nasdaq bid-price compliance.

What are the key timelines for LNCB74 and SIM0505 trials?

NextCure expects LNCB74 back-fill cohorts in 2H-25 and proof-of-concept data 1H-26; first U.S. patient for SIM0505 is targeted in 3Q-25 with initial update 4Q-25.
Stock NXTC logo
Nextcure

NASDAQ:NXTC

NXTC Rankings

#5919 Ranked by Market Cap
N/A Ranked by Dividends

NXTC Latest News

Sep 4, 2025
NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Aug 7, 2025
NextCure Provides Business Update and聽Reports Second Quarter 2025 Financial Results
Jul 24, 2025
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta
Jun 16, 2025
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
May 29, 2025
NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

NXTC Latest SEC Filings

Aug 25, 2025
[8-K] NextCure, Inc. Reports Material Event
Aug 19, 2025
[SCHEDULE 13G] NextCure, Inc. SEC Filing
Aug 19, 2025
[Form 3] NextCure, Inc. Initial Statement of Beneficial Ownership
Jul 18, 2025
[S-3] NextCure, Inc. Shelf Registration Statement
Jul 14, 2025
[8-K] NextCure, Inc. Reports Material Event

NXTC Stock Data

13.46M
2.28M
14.79%
32.58%
3.29%
Biotechnology
Pharmaceutical Preparations
United States
BELTSVILLE